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SUMMARY 
Coronary arterial disease is responsible for approximately 18 million deaths 
worldwide including more than four million in Europe. Although mortality is 
decreasing, its prevalence is rising. After a cardiac event, secondary prevention 
plans such as cardiac rehabilitation are recommended. Cardiac rehabilitation is a 
multidisciplinary program that includes dietary modification, lipid control, smoking 
cessation, psychological counselling, pharmacological therapies and structural 
exercise training as the core component. Its effects on reducing mortality, prevention 
of hospital readmissions and improvement of quality of life are highly proved. 
However, it is still underutilized partially because one model does not fit all patients. 
Hence, innovative ways of delivering cardiac rehabilitation have been studied. One 
of those technologies is tele-monitoring; through cardiac tele-rehabilitation some 
traditional barriers of cardiac rehabilitation programs can be address and it 
represents an alternative or a supplement to conventional centre-based services. 
Thus, patients would not be restricted to the hospital or rehabilitation centre and 
could be controlled at a distance. 
Cardiac tele-rehabilitation has shown to be as effective as traditional centre-based 
cardiac rehabilitation on early stages of the program. However, the information 
regarding the maintenance phase is scarce. Thus, the main purpose of this doctoral 
research was to investigate the short and long-term effectiveness of a home-based 
exercise program guided through tele-monitoring in patients starting the 
maintenance phase (phase III) of cardiac rehabilitation compared to a centre-based 
group as well as a control group through an intervention study (TRiCH = Tele-
rehabilitation in Coronary Heart Disease study). 
From our results in the short-term (3 months) we can conclude that a home-based 
cardiac rehabilitation program with tele-monitoring guidance is as effective as centre-
based cardiac rehabilitation for improving exercise capacity measured as peak 
exercise capacity (VO2P).  
During the intervention, exercise capacity increased in home-based and centre-
based groups with on average 4 to 5% with clinical significance while it remained 
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stable in the control group. In the long-term, we did not obtain further increases 
although exercise capacity remained stable in all three groups. This result might be 
related to the maintenance of physical activity levels of our population. In the TRiCH 
study, 85% of patients meet the guidelines of the World Health Organization of at 
least 150 minutes of physical activity per week at a moderate intensity. 
Being physically active is one of the cornerstones on lifestyle changes for primary 
and secondary prevention of coronary artery disease and new technologies are 
useful tracking patient’s training. During the development of this PhD research, 
facing the wide variety of tracking products available to the public, we explored the 
accuracy of some devices. Our interest was also increased by the scarcity of 
published literature related to validity and reliability of such devices. We concluded 
that Fitbit Charge HR and MIO Fuse are valid and reliable to measure number of 
steps in a cardiac population, however, when it comes to energy expenditure we 
documented a noteworthy inability including also the SenseWear Armband Mini and 
the Actiheart to estimate it accurately. 
Nutrition is also considered a part of the lifestyle changes for coronary artery disease 
patients and a number of nutritional supplements have flooded the market in a similar 
manner as that of activity trackers. Resveratrol is a natural antioxidant present in red 
wine that has proved beneficial effects in the cardiovascular system of animals 
(specially rats), however, when it comes to human studies, few information has been 
published. Based on the cardio protective effect shown in animal models we 
intended to study if an acute supplementation with high doses of RV would improve 
endothelial function measured through flow-mediated dilation in cardiac patients on 
phase III of cardiac rehabilitation. We concluded that resveratrol impaired flow 
mediated dilation in patients who underwent percutaneous coronary intervention. 
However, given the few number of participants, our results must be interpreted 
cautiously.    
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SAMENVATTING 
Coronair arterieel lijden is verantwoordelijk voor ongeveer 18 miljoen sterfgevallen 
wereldwijd, waarvan meer dan vier miljoen in Europa. Ondanks dat de 
mortaliteitscijfers dalen, blijft de prevalentie van coronair arterieel lijden stijgen. Na 
het doormaken van een cardiaal event, is het aangewezen om een secundair 
preventieprogramma zoals cardiale revalidatie, te volgen. Een cardiaal 
revalidatieprogramma is van nature multidisciplinair, maar de kern bestaat uit 
gestructureerde training. Verder omvat het nog voedingsadvies, controle van het 
lipidenprofiel, rookstopbegeleiding en het op punt stellen van de medicamenteuze 
therapie. De effecten van cardiale revalidatie op het verlagen van de mortaliteit, het 
voorkomen van nieuwe ziekenhuisopnames en het verhogen van de levenskwaliteit, 
zijn al uitvoerig aangetoond. Nochtans wordt cardiale revalidatie de dag van 
vandaag nog onderbenut. Het feit dat cardiale revalidatie een schoentje is dat niet 
iedereen past, zit daar zeker voor iets tussen. Daarom wordt er ijverig gezocht naar 
nieuwe manieren om cardiale revalidatie aan te kunnen bieden. Eén van die 
manieren is het gebruik van technologie onder de vorm van telemonitoring. Door 
telemonitoring kunnen sommige barrières overwonnen worden die anders de 
deelname aan cardiale revalidatie zouden verhinderen. Op die manier kan 
telerevalidatie gezien worden als zowel een alternatief alsook een aanvulling op de 
traditionele ambulante cardiale revalidatie. De patiënt hoeft dus niet meer afhankelijk 
te zijn van een ziekenhuis of revalidatiecentrum voor een groot deel van zijn 
revalidatie en kan van op een afstand in de gaten gehouden worden. 
Het is al aangetoond dat cardiale telerevalidatie even effectief kan zijn als 
traditionele hartrevalidatie wanneer gekeken wordt naar de eerste fases van het 
programma. Over de langetermijneffecten is echter nog weinig geweten. Daarom 
was het hoofddoel van dit doctoraatsproject om zowel de effecten op korte als 
langere termijn te onderzoeken van een trainingsprogramma dat door de patiënt in 
de thuisomgeving werd uitgevoerd en gebruik maakte van telemonitoring. Het betrof 
patiënten die met succes een revalidatieprogramma in het ziekenhuis hadden 
doorlopen en de onderhoudsfase (fase III) van cardiale revalidatie ingingen. De 
telemonitoring groep werd vergeleken met een groep die langer in het ziekenhuis 
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trainde alsook met een controle groep d.m.v. een interventiestudie (TRiCH = 
TeleRehabilitation in Coronary Heart Disease study). 
Uit de resultaten op korte termijn (3 maanden) concluderen we dat thuisrevalidatie 
met telemonitoring even effectief is als een langere trainingsperiode in het 
ziekenhuis wanneer het aankomt op het verbeteren van de inspanningscapaciteit. 
De inspanningscapaciteit  (IC) werd gemeten door zuurstofconsumptie tijdens een 
maximale inspanningsproef op de fiets. Tijdens de interventie steeg de IC in deze 
groepen met 4-5%, wat klinisch significant is. De IC bleef constant in de 
controlegroep. Op lange termijn (1 jaar) zagen we geen verdere stijging van de IC, 
maar de waarden bleven wel constant in alle drie de groepen. Dit kan te wijten zijn 
aan het behoud van goede hoeveelheden fysieke activiteit in onze steekproef. Van 
de deelnemers aan de TRiCH studie, voldeed 85% aan de richtlijnen voor fysieke 
activiteit zoals opgesteld door de Wereld Gezondheid Organisatie waarbij een 
minimum van 150 minuten matig intense inspanning per week wordt nagestreefd. 
Fysiek actief zijn is één van de hoekstenen van primaire en secundaire preventie 
van coronair arterieel lijden. Nieuw ontwikkelde technologieën kunnen nuttig zijn om 
dit gedrag van de patiënt te monitoren. Tijdens de totstandkoming van dit 
doctoraatsproject werden we geconfronteerd met een grote variëteit van 
beschikbare producten en daarom hebben we de accuraatheid van enkele van deze 
monitors onderzocht. Deze onderneming werd gesteund door de vaststelling dat er 
maar zeer weinig wetenschappelijke literatuur omtrent de validiteit en 
betrouwbaarheid van zulke apparaten bestond. Uit ons onderzoek kwam naar voor 
dat de Fitbit Charge HR en MIO Fuse valide en betrouwbaar zijn om het aantal 
stappen te meten in een populatie met hartproblemen. Echter, wanneer het aankomt 
op het meten van het energieverbruik merkten we noemenswaardige 
tekortkomingen bij voornoemde apparaten, maar ook bij de SenseWear Armband 
en de Actiheart. 
Zoals al eerder aangehaald is voedingsadvies ook een belangrijke component in de 
multidisciplinaire hartrevalidatie. Een groot aantal voedingssupplementen hebben 
de markt op een gelijkaardige manier overspoelt zoals dat ook bij fysieke 
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activiteitsmonitors gebeurd. Resveratrol (RV) is een natuurlijk antioxidant dat veel 
voorkomt in rode wijn en waarvan de positieve effecten op het cardiovasculair 
systeem zijn aangetoond bij dieren (vooral ratten). Wanneer het aankomt op mensen 
is er echter maar weinig informatie beschikbaar. Daarom onderzochten we of acute 
hoge doses RV supplementatie de endotheelfunctie bij hartpatiënten in fase III van 
de hartrevalidatie kon verbeteren. Dit deden we door middel van een flow-mediated 
dilatatie meting (FMD). Onze resultaten toonden aan dat RV de FMD verslechterde 
bij patiënten die een percutane coronaire interventie hadden gehad. Het is wel zo 
dat onze studiepopulatie heel klein was waardoor de resultaten met enige 
voorzichtigeid geïnterpreteerd dienen te worden. 
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Cardiovascular disease is defined by the World Health Organization as a group of 
disorders of the heart and blood vessels and include coronary artery disease (CAD), 
cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, 
congenital heart disease, deep vein thrombosis and pulmonary embolism (1). 
Cardiovascular diseases (CVD) remain the leading contributor to global mortality and 
morbidity. Globally, it is responsible for approximately a third of all yearly deaths, 
with mortality rates in high-income countries ranging from 20% to 50% (2).   
Notable progresses have been observed in the treatment of CVD. As a result, a 
decline in age-standardized CAD and CVD mortality has been observed in many 
European countries since the 1970s being most prominent  in the more affluent 
countries, illustrating the potential for premature death prevention  and prolonged 
healthy life expectancy (3). Despite these progresses, incidence of new and 
recurrent CAD remains high (4), and is expected to increase health care costs, work 
disability and reduce quality of life (4). Furthermore, global deaths from CVD have 
risen by 41% between 1990 and 2013 (5), with ischemic heart disease becoming the 
leading cause of global deaths and stroke  risen to third position (6). In Europe, more 
than 4 million people die from CVD across the continent every year, with more than 
1.4 million dying prematurely, before 75 years of age (7). In several eastern 
European countries, CVD and CAD mortality remains high. 
Pathophysiology of Coronary Artery Disease (CAD) 
The underlying pathophysiologic mechanisms of coronary heart disease or coronary 
artery disease (CAD) begin with the process of atherosclerosis, which develops and 
progresses for decades prior to an acute event. Atherosclerosis can be considered 
as a low-grade inflammatory state of the intima (inner lining) of medium-sized 
arteries, accelerated by risk factors such as high blood pressure, smoking, high 
cholesterol, diabetes, and genetics (8). In the case of coronary atherosclerosis, this 
slow progression leads to a gradual thickening of the inner layer of the coronary 
arteries, which in time narrow the lumen of the artery to various degrees, leading to 
acute syndromes such as myocardial infarction (AMI) and sudden cardiac death 
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(SCD). Atherosclerosis is more common in the proximal segments of the major 
coronary arteries often at arterial bifurcation points affecting the flow in the artery (8). 
Risk factors 
An estimated 75% to 90% incidence of CAD in a variety of populations can be 
explained by antecedent exposure to conventional lifestyle risk factors,  including 
poor dietary habits, physical inactivity, and cigarette smoking (9). Risk factors for 
CAD can be divided into modifiable (hypertension, diabetes mellitus, smoking, 
physical inactivity, dyslipidaemia, obesity, stress and diet) and non-modifiable risk 
factors (gender, age, and family history) (10).  
Modifiable risk factors 
Cigarette smoking increases the risk of morbidity and mortality from ischemic heart 
disease compared with not smokers; this risk falls immediately after stopping 
smoking, although it may take more than 20 years, before the risks associated with 
smoking are completely reversed (11). However, the global prevalence of tobacco 
smoking in people aged 15 years and older has declined from 27% in 2000 to 21% 
in 2013, being largest in developed countries (12). With the decline of cigarette 
smoking, dyslipidaemia has become the number one modifiable risk factor for CAD 
(13).  
The crucial role of dyslipidaemia, especially hypercholesterolaemia, in the 
development of CVD is well documented with pathology, genetic, intervention and 
observational studies (14). Most cholesterol is normally carried in LDL-C (14), and 
an elevated low-density lipoprotein (LDL) cholesterol levels account for 
approximately half the population-attributable risk of an acute cardiac event (15) and 
around one quarter of the risk of stroke (16). Hypertriglyceridaemia is also a 
significant independent risk factor, although the risk is associated bigger with 
moderate hypertriglyceridaemia that with very severe hypertriglyceridaemia 
[>10mmol/L] (14).   
High blood pressure is a major public-health challenge globally; it is estimated to be 
responsible for 7.5 million deaths annually, and is predicted to increase with 
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population aging and growth (17); elevated blood pressure is considered the most 
significant global risk factor for cardiovascular morbidity and mortality and exhibits 
the highest prevalence in the world, although being approachable by different 
antihypertensive treatments (18).  
Over the past three decades, the burden of diabetes mellitus (DM) has increased 
from 30 million in 1985 to 382 by 2014, with current trends indicating a raising in the 
numbers (19), estimating that by the year 2035, one in ten persons will have DM 
(592 million worldwide) (20). A close link exists between DM and CVD, being the 
direct cost of DM attribute to macro and micro vascular complications; furthermore, 
there is an increased risk of CVD mortality in diabetic patients with a relative risk 
ranging from 1 to 3 in men and from 2 to 5 in women compare to those without DM 
(21). These traditional risk factors are established as mediators between obesity and 
atherosclerotic vascular disease, making obesity a common risk factor for several 
CVD (22).  
Excess body weight is estimated to cause approximately 3 million deaths every year 
(23) and although weight management is fundamental in the treatment of CVD 
prevention, the majority of obese individuals do not achieve sufficient and sustained 
weight loss. Thus, there is a great emphasis on controlling the traditional CVD risk 
factors resulting from obesity as a strategy for reduction in CV risk (24). The main 
dietary factors that impact CV mortality include trans-fat, saturated fat, salt and 
insufficient vegetables and fruits; in fact, insufficient intake of fruit and vegetables is 
estimated to cause approximately 11% of ischaemic heart disease deaths and 9% 
of stroke deaths worldwide (12). Diverse dietary patterns can be adopted where a 
high predominance of vegetables and fruits, wholegrain cereals and low-fat protein 
sources would have more importance that the precise proportions of total energy 
obtained by the major macronutrients. In the same line, salt intake should be 
restricted, and limiting saturated and trans fats and alcohol consumption, plus 
monitoring of carbohydrate consumption and an increase in dietary fibre should be 
recommended (14).  
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A wide variety of stressors including mental, social and work stress could also 
influence the presence of CVD through  a general adaptation syndrome (25). This 
syndrome has been described in earlier research and consists of three phases, 
being “fight or flight” response the first phase, which prepares the organism for the 
challenge of the stressful stimuli. The second phase represents the chronic 
adaptation to the stressful stimuli, and the last phase constitutes a state of fatigue, 
where the adaptive system begins to fail (25). Selye’s hypothesis that excessive 
mental stress leads to systemic stress, that manifest in peripheral tissues and that 
these psychological modulations are closely associated with the pathogenesis of 
CVD are now well accepted (26). In fact, psychosocial stress and/or depression are 
stronger risk factors for myocardial infarction than traditional risk factors such as 
hypertension or obesity (27). Figure 1 describes the mechanism(s) underlying the 
exacerbation of CVD due to mental stress.  
Currently, data are limited on trends in physical inactivity worldwide (12); however, 
in 2010, 23% of adults older than 18 years of age were insufficiently physically active 
having a prevalence of 33% of physical inactivity in high-income countries (1). 
Physical inactivity has a deleterious effect comparable to smoking or obesity (28), in 
fact, Wen and Wu (29) estimated that because of the remarkably high prevalence of 
physical inactivity, a sedentary lifestyle kills more people worldwide than smoking. 
In addition to the relationship between level of physical activity and CVD, the concept 
of sedentary time and sedentary behaviour has recently emerged as a new risk 
factor for morbidity and mortality (30). Consequently, even when not achieving 
recommended physical activity levels, getting the population out of their sedentary 
behaviours would, at least theoretically have a huge public health effect on morbidity 
and mortality from CVD (31).   
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Figure 1. Mental stress induces two kinds of responses: physiological and behavioural. 
Physiologically, the sympathetic nervous system and HPA axis are activated. Follow this activation, 
a wide variety of cellular events are involved in the pathogenesis of CVD. Additionally, various stress-
responsive humoral factors are regulated, including neurotrophins and urocortin. Adapted from Inoue 
et al (26). 
 
Non-modifiable risk factors 
Importantly, 10% to 15% of patients with CAD have no apparent major CAD risk 
factors. Family and twin studies suggest a strong genetic influence on premature 
CAD.  Results from the Framingham Offspring Study demonstrate that, after 
correction for known risk factors, parental CVD was associated with a 1.7 and 2.0-
fold increased risk for women and men, respectively (32). The risk also varies 
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considerably between ethnicity. South Asians and sub-Saharan Africans have a 
higher risk, while Chinese and South Americans have a lower risk of CVD (14). 
Finally, numerous studies have shown that CAD occurs more frequently in men than 
in women (7.9 and 5.1% in men and women >20 years old, respectively) (33). This 
trend however, reverses in older age (>75 years), possibly due to menopause and 
related hormonal changes in women (34). Figure 2 resumes the main risk factors 
associated with cardiovascular disease. 
 
 
Figure 2. The individual development of CVD can be modified by a number of risk factors. These fall 
into two categories: modifiable and not-modifiable risk factors. As modifiable risk factores, these may 
have both a negative (increase risk) and a positive (lowered disease risk) impact on the likelihood of 
an individual developing of CVD. Adapted from Laher (35). 
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Diagnosis 
These traditional risk factors (smoking, hypertension, diabetes, hyperlipidemia, 
physical inactivity) together with a family history of myocardial infarction before the 
age 60 years, increase the likelihood of CAD. 
The medical history identifies relevant comorbidities and should include details of 
patient diet, physical activity, and relevant social history including tobacco and 
alcohol use and family history of heart disease (36). Physical examination is often 
not able to reveal CAD, however, examination remains essential because these 
findings may be important in determining the risks and benefits of a comprehensive 
treatment strategy and the need for additional investigations (37). 
Currently the guidelines recommend a systematic approach to CV risk assessment 
targeting populations at higher risk such as those with family history of premature 
CVD (14). Non-invasive cardiac investigation could include standard laboratory 
biochemical testing, a resting ECG, an ambulatory ECG monitoring as well as a 
resting echocardiography and in selected patients a chest X-ray (38).  
Treatment 
The aim of the management of CVD is to reduce symptoms, improve prognosis and 
prevent future CV events. The management of CVD patients encompasses lifestyle 
modification, control of CVD risk factors, evidence-based pharmacological therapy 
and patient education (39).  
Patients with CAD are considered at very high risk for cardiovascular events and 
statin treatment should be considered, irrespectively o low density lipoprotein 
cholesterol (LDL-C) levels (39).  The goals of treatment include LDL-C below 
1.8mmol/L or >50% LDL-C reduction if target level cannot be reached (39).  
Is recommended that SBP be lowered to <140 mmHg and DBP to <90 mmHg in 
stable CAD patients with hypertension (39). Provided that the treatment is well 
tolerated, treated BP values should be targeted to 130/80 mmHg or lower in the 
majority of patients (40). Most patients will require (in addition to lifestyle 
modifications) drug therapy in order to achieve optimal BP control. Currently, five 
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major drug classes are recommended for the treatment of hypertension: ACE 
inhibitors (angiotensin-converting enzyme), ARBs (angiotensin receptor blocker), 
beta-blockers, CCBs (calcium channel blockers), and diuretics (thiazides and 
thiazide-like diuretics such as chlortalidone and indapamide) (40).  
Diabetes mellitus increases the progression of CAD and should be manage carefully. 
Currently, a glycated hemoglobin (HbA1c) <7.0% and <6.5 – 6.9% on individual 
bases is recommended (39).  
Latest advance in techniques, equipment, stent and adjuvant therapy have 
established PCI as a routine and safe procedure in patients with stable CAD and a 
suitable coronary anatomy (38). The decision of revascularize a patient should be 
based on the presence of significant obstructive coronary artery stenosis, the 
expected benefit on prognosis and or symptoms and the amount of related 
ischaemia (38). Revascularization can also be considered as a first-line treatment in 
post-myocardial infarction, angina/ischaemia, mustivessel disease, left ventricular 
dysfuction and/or large ischaemic territory, left main stenosis (38). The indications 
for PCI and CABG in stable CAD patients have been clearly described by Windecker 
et al (41). Stable CAD patients treated with PCI irrespective of the type of metallic 
stent implanted, should have a dual antiplatelet therapy between 1 to 6 months 
depending on the bleeding risk. Insufficient data exist for patients treated with CABG, 
thus dual antiplatelet therapy is not recommended (42). 
Cardiac rehabilitation (CR) is a central element  in contemporary CVD management 
that aims to optimize cardiovascular risk reduction, facilitate adoption and adherence 
to healthy behaviours, reduce disability and promote an active lifestyle (43). 
Following a cardiac event, secondary prevention by means of cardiac rehabilitation 
(CR) is a Class IA recommendation in the treatment of patients with CAD by the 
European Society of Cardiology (ESC) (44), the American Heart Association and the 
American college of cardiology (45).  
CR is a multifaceted and multidisciplinary intervention, which improves functional 
capacity, recovery and psychosocial well-being. It has been shown to be a cost-
effective intervention following an acute coronary event and chronic heart failure, as 
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it improves prognosis by reducing recurrent hospitalization and health care 
expenditures, while prolonging life (45). 
The World Health Organization has offered a definition of CR that summarizes very 
well its objectives: i.e. the sum of activities required to influence favorably the 
underlying cause of the disease, as well as to ensure the patient the best possible 
physical, mental and social conditions, so that they may, by their own efforts, 
preserve or resume when lost, as normal a place as possible in the life of the 
community (World Health Organization; 1993) (46). 
CR focusses on secondary prevention which relies on early detection of the disease 
process and application of interventions to prevent the progression of disease (47). 
Over the past decade, secondary prevention and CR programs have moved on from 
being simple interventions to much more complex services that include more 
comprehensive professional lifestyle interventions based on behavioural models of 
change (i.e. smoking cessation, healthy food choices and exercise training) with 
different. Risk factor management in terms of effective control of blood pressure, 
lipids and glucose to defined targets, and the appropriate prescription and adherence 
to cardio-protective drugs are now integral parts of this approach. Finally, the 
psychosocial and vocational supports required to help patients regain a life as full as 
possible are also provided (48). Nonetheless, international clinical guidelines 
consistently identify exercise as a central element of CR (49). Four previous meta-
analyses of the effects of exercise-based interventions in patients with CAD reported 
a statistically significant benefit in patients receiving exercise compared with usual 
medical care, with a reduction in total and cardiac mortality ranging from 20% to 32% 
(49). Current components of CR can be seen in Figure 3. 
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Figure 3. Core components of CR/secondary prevention programs. Adapted from Sandesara et al 
(9).  
 
Phases of CR 
Traditionally, CR is divided into three phases. All phases of CR aim to facilitate 
recovery and to prevent a new cardiovascular event (47).  
Phase I or the inpatient phase initiates while the patient is still in the hospital. It 
consists of early progressive mobilization once the patient is stable to a level of 
activity required to perform simple household tasks. Inpatient CR programmes are 
mostly limited to early mobilization to make self-care possible by discharge, and brief 
counselling about the nature of the illness, risk factors management, the treatment 
and follow-up planning (47). 
Phase II is a supervised ambulatory outpatient programme lasting usually between 
3 to 6 months which consists of outpatient monitored exercise and aggressive risk 
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factor reduction. Yet, in many countries (especially in Europe), residential programs 
of 3 to 4 weeks duration are offered (47). 
Phase III is a lifetime maintenance phase in which physical fitness is a cornerstone 
and additional risk-factor reduction are emphasized. It consists of home or 
gymnasium-based exercise with the goal of continuing the risk factor modification 
and exercise programme learned during phase II (47). 
Referral of CR 
Despite the well-known benefits of CR, referral and uptake of supervised centre- 
based (CB) CR are inadequate (50).  Based on data from the EuroAspire study of 
CVD management, 44.8% of CR-eligible patients are being referred to a CR program 
whereas only 36.5% participates in a CR program (51). In 2007 a Belgian report 
suggested that only 15-30% of patients for whom CR may be beneficial, use this 
service (52). These rates have not improved since the 2002 publication of the 
Carinex project (53). There are common aspects affecting participation and 
adherence to CR programs. In fact, predictors of poor participation in CR have been 
widely studied through quantitative analysis and include distance from CR centre, 
lower socioeconomic status, female gender, ethnicity and older age (54). Regarding 
accessibility, proximity to a health centre offering CR programs, plays an important 
role in participation and adherence (55). Patients regularly choose not to attend the 
rehabilitation sessions in the hospital due to ill-health, a lack of transport, time and 
scheduling commitments associated with returning to work and / or reimbursement 
problems (56). Furthermore, in many countries, legislation with regard to CR is 
inadequate or non-existing; there is a lack in reimbursement and know-how with 
regard to implementation of guidelines that could support the referral and access to 
CR (57).  
Long-term benefits are even more disappointing, mainly due to low CR uptake, low 
adherence rates (2) and the lack of resources regarding phase III CR. Evidence is 
emerging that most patients fail to achieve secondary prevention targets in the long 
term; in fact, many patients need support to maintain physical activity as well as 
other health related lifestyle changes. Thus, whereas phase III ought to support the 
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benefits obtained in phase II; it appears to be somewhat “invisible” today. In many 
countries, the impression is that implementation of phase III is led by patients instead 
of health care providers (58). Consequently, although most cardiac patients adopt 
healthier lifestyles during CR, many relapse into old habits when returning to 
everyday life. Excluding medication adherence, that seems to be improved after 
enrolment in CR (59), research on the maintenance of other CR benefits shows that 
up to 60% of patients after a centre-based CR program relapse over the first six 
months (60). Hansen et al. showed that only one out of four patients with CAD 
adhere to the recommended physical activity level of CR at 18 months follow-up (56). 
In the same line, Twadella et al (61), proved that CR patients receiving dietary 
intervention achieve a higher median intake of recommended food items (low-fat 
sausage, margarine, cheese, wholemeal bread) and lower median consumption of 
high-fat and not recommended food items (French fries, milk, eggs, white bread, 
cake) compared with their dietary habits1 year before their enrolment. However, this 
change was not maintained up to 1 year after CR.  
Alternative models for CR 
Currently CR delivery approaches do not suit everyone and new innovative ways are 
needed to match patient preferences in order to improve uptake and compliance to 
a life-long physically active lifestyle among cardiac patients (62, 63) after completion 
of hospital-based CR (4).   Different strategies for secondary prevention range from 
multidisciplinary and specialized modalities in the hospital setting to family-based 
interventions in the long term (57). While there is no general consent upon definition 
of home or community-based CR, several guidelines recommend delivery of the 
same established core components of in-hospital CR program, including structured 
exercise, patient education and counselling (64). In home-based CR, a patient 
comes in the CR centre for an initial assessment, where patient safety for 
independent exercise is established and an exercise prescription is developed. 
Then, exercise training is performed without formal supervision, and regular contact 
through different technologies are made to deliver other components or review 
exercise (64). On the other hand, community-based CR exploit community exercise 
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facilities where CR staff go and deliver comprehensive services (64). Is estimated 
that 15% of patients in Australia (65), 12% in New Zealand (66), 28% in Europe (53), 
and 38% in Mexico (67) participate in some form of alternative model of CR. 
Supervised-CR programs 
CR programs differ considerably worldwide and across randomized controlled trials 
in duration (one to 30 months), frequency (one to seven sessions/week) and session 
length (20 to 90 minutes/session), and also vary in the inclusion of exercise-only or 
comprehensive programmes (exercise plus psychological or education intervention 
or both) (68). Heran et al. found a trend towards larger reduction in total mortality 
(RR 0.82; 95% CI 0.67 to 1.01) in the CR group compared to the no-CR control up 
to six to 12 months of follow-up, and a reduction in overall mortality and 
cardiovascular mortality with follow-up of 12 months or more. Currently, CR is 
predominantly delivered in a supervised group-based model and only a small 
proportion provided other modes to their patients (69). Traditionally, it is assumed 
that a supervised group-based is the best approach for influencing outcomes; 
however there is an emerging trend in recent years to offer models based on 
facilitated self-management (69).  
Community-based CR 
According to Lima et al (64), community-based programs are delivered in 25 
countries with an average of 20 sessions, usually supervised by an exercise 
physiologist or physiotherapist and involved usually a cardiologist or physiatrists. 
Programs are usually on the basis of choice, risk or indication and distance or 
transportation (64).  
Home-based CR 
Home-based (HB) rehabilitation programs might overcome some of the barriers for 
attending a centre-based (CB) CR program and target a broader range of patients 
who would benefit from CR (70). Meta-analyses showed that HB rehabilitation can 
be at least as effective as supervised rehabilitation for maintaining exercise capacity, 
with some evidence of higher levels of program completion and adherence up to 12 
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months (70). HB cardiac tele-rehabilitation seems to be a promising tool for stable 
CAD patients (71). 
Telemedicine is the utilization of medical information transferred remotely via digital 
communication to improve or promote the health of patients, and is progressively 
becoming common practice of medicine in many areas of the world (72), in CR, 
recent advances in information and telecommunication technologies, such as 
smartphones and the internet, have enabled the advent of cardiac tele-rehabilitation 
programs (2).  
Tele-rehabilitation is part of telemedicine and is defined as the application of 
telecommunication technology that provides distant support, assessment and 
intervention to individuals with disabilities (73). The benefits of using tele-
rehabilitation include: 1) decreased travel between rural communities and 
specialized urban health centres; 2)improved access to specialized services; 3) 
better clinical support in local communities; 4) delivery of local health care in rural 
communities; 5) reduced feelings of isolation for rural clinicians indirect educational 
benefits for remote clinicians who participate in teleconsultations; 6) improved 
service stability in regions with high staff turnover; and 8) multimedia communication 
(74).   
In tele-rehabilitation, the patient is monitored from a distance and receives regular 
feedback. Thus, patients are no longer restricted to the hospital environment as in  
exercise-based CR, and learn to implement the exercise in their daily routine at 
home (4). These new methods of health care delivering whether using mobile digital 
communication devices or mobile health (mHealth), may increase the number of 
patients treated while facilitating patient self-management and saving costs (72). 
Tele-rehabilitation also have the potential to increase the number of cardiac 
rehabilitation components delivered to the patients. Different models of HB cardiac 
tele-rehabilitation have been present, the use of heart rate monitors are considered 
the less sophisticated as well as the trans telephonic electrocardiographic 
monitoring, whereas more advanced systems are using tele-ECG-monitoring via a 
remote device and real-time ECG and voice trans telephonic monitoring (71). 
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The use of wearable physical activity trackers also offers great promise to 
researchers and clinicians aiming to promote a physical active lifestyle and have the 
potential to affect physical activity behaviour of patients (75). A recent report found 
that 77% of adults over 65 years old owned a mobile phone and over half (59%) 
used the Internet (76). Furthermore, since 2011, there has been a 30% increase in 
ownership of smartphones with nearly 62% of smartphone owners reporting using 
their cell phone to seek health information within the past year (77). Hence, the 
introduction of a home-based exercise therapy with tele-monitoring guidance carries 
the potential to improve compliance to exercise-based CR today.  
However many challenges remain to increase the benefits of CR programs. 
Therefore, the particular aim of this PhD-project was:  
- To evaluate the short (3-months) and longer-term (one-year) effectiveness 
of a home-based exercise program in patients completing a phase II 
centre-based CR program 
 
The majority of exercise intervention studies in CAD patients examined the effects 
of short (up to 3 months) CR programs and follow-up studies reported poor long-
term adherence to physical activity recommendations and a decline in exercise 
capacity (78), however the majority of these interventions have not undergone 
rigorous trials for efficacy (77). Consequently, in chapter 1 we describe the research 
protocol of the Tele-Rehabilitation In Coronary Heart disease (TRiCH-study).  In 
chapter 2 we report on the short-term effect of a home-based CR program with tele-
monitoring guidance on physical fitness and other secondary outcomes in CAD 
patients following completion of a centre-based CR program. Chapter 3 evaluates 
the added benefit in the longer-term (i.e. one year after completion of ambulatory CR 
program) of a home-based program with tele-monitoring guidance on physical 
fitness and its effectiveness to a prolonged centre-based (CB) CR intervention. It is 
worth clarifying that although CR incudes core components such as nutritional 
counselling, risk factor management, psychosocial management on top of physical 
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activity training; this PhD research focussed exclusively on exercise training with 
tele-monitoring support. 
Finally despite the widespread adoption and potential application of monitor tracking 
devices in health care, there is little information about their accuracy and reliability 
(79). Since living a physically active lifestyle has profound and multiple benefits not 
only in healthy young individuals but also in older adults and specially populations 
living with chronic illnesses like CVD, chapter 4 determines the validity and reliability 
of some consumer and more research based physical activity devices to assess 
energy expenditure (EE) and step count in a phase III CR population under well-
controlled laboratory conditions; this in an effort to increase the understanding of the 
precision of several assessment tools available in the market and commonly used 
to evaluate  physical activity behaviour in the CAD population. 
Completing the particular aims of this PhD-project and as part of the requirements 
of the joint doctorate program “MOVE-AGE”, Manchester Metropolitan University 
joined the fellowship as a “host” university and a project was developed between 
both institutions. The consumption of Mediterranean-style diets, which are rich in 
resveratrol, are associated with a reduced risk of cardiovascular mortality in humans 
(80). Thus, our aim was to determine the acute effect of supplementation with high 
doses of resveratrol, a nutraceutical supplement, on endothelial function and oxygen 
consumption in patients with coronary artery disease. The research developed 
between both institutions is part of the appendices of the present document. 
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ABSTRACT 
 
Aerobic exercise capacity (VO2P) and an active life style are related to long-term 
survival and to a reduction in cardiovascular morbidity in subjects with cardiovascular 
disease. However, the majority of cardiac patients do not engage enough in physical 
activity (PA) to obtain or maintain the benefits of a physically active lifestyle. There 
is a need for innovative rehabilitation methods aiming at increasing longer-term 
adherence and hence more sustained effects on physical fitness. One strategy might 
be the use of home-based training in combination with tele-monitoring guidance.  
 
Here we describe the rationale, design and methods of the Tele-Rehabilitation in 
Coronary Heart disease study (TRiCH). The main objective of TRiCH is to compare 
the longer-term (=1 year) effects of a 3-month patient-tailored home-based cardiac 
rehabilitation program with tele-monitoring guidance with a supervised centre-based 
cardiac rehabilitation program in coronary artery disease patients (phase III).  
 
The study is planned as a randomized controlled prospective trial that will randomize 
105 coronary artery disease patients (40-75 yrs) who have successfully completed 
a three month ambulatory cardiac rehabilitation program (phase II) to one of the 
three groups: home-based, centre-based or a control group (usual care) on a 1:1:1 
basis. The exercise programs (frequency, intensity and time of exercise) of patients 
randomized to home-based or centre-based will be designed according to current 
exercise recommendations. Patients in the control group will receive the advice to 
maintain a physically active lifestyle. Assessments will be performed at baseline, 
after 12 weeks of intervention and at one year of follow-up. The primary outcome 
measure is change in exercise capacity assessed by VO2P at 3 and 12 months of 
follow-up. Secondary outcomes include determinants of exercise capacity, i.e. PA, 
endothelial function and muscle function, as well as traditional cardiovascular risk 
factors and quality of life.  
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It is hypothesized that home-based training with tele-monitoring guidance will result 
in higher levels of VO2P at one year of follow-up. Enrolment started in February 2014; 
last enrolment is expected in November 2015. 
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INTRODUCTION 
Cardiovascular diseases are the leading cause of death, responsible for 30% of all 
deaths worldwide (1). It is widely recognized that secondary cardiovascular 
prevention programs play a pivotal role in optimizing recovery in cardiac patients, 
with meta-analyses demonstrating reduced morbidity and mortality (2). Exercise is 
a cornerstone therapy in these Cardiac Rehabilitation programs as it has been 
consistently shown to increase exercise capacity and subsequently decrease 
cardiovascular risk factors, morbidity and all-cause mortality in patients with coronary 
heart disease (CHD) (3, 4). Given the strong association between higher exercise 
capacity and favourable prognosis in those with coronary artery disease, it should 
be no surprise that maintaining a physically active lifestyle is of utmost importance. 
However, CR is dramatically underutilized. Recent data from the EuroAspire study 
of cardiovascular disease management showed that only 44.8% of eligible patients 
had evidence of referral and 36.5% evidence of participation in rehabilitation (5). 
These data show that participation rates have not substantially improved since the 
2002 publication of the Carinex project (6).  
Barriers to participation besides low referral rates, include patient difficulty attending 
centre-based (CB) rehabilitation sessions and cost. Even if patients gain knowledge 
about the importance of physical activity (PA) and improve their exercise capacity 
during the structured cardiac rehabilitation programs, most fail to translate this into 
a lifelong physically active lifestyle (7). Hansen et al., (8) demonstrated that only 27% 
of patients that participated in an centre-based program adhered to the minimal PA 
level that is required to obtain significant health benefits at 18 months following the 
ambulatory rehabilitation program. In line, Reid et al. found a significant decrease in 
habitual PA during long-term follow up after hospital discharge in patients with 
coronary artery disease (9). Therefore, graduation from a supervised to an 
unsupervised environment constitutes a pivotal event that is often associated with a 
decline in PA and fitness levels resulting in a worsening of cardiovascular risk profile 
(10, 11).  
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There is a need for innovative rehabilitation methods aiming at increasing longer-
term adherence to a physically active lifestyle and hence more sustained effects on 
health related physical fitness, and in the end morbidity and mortality. One strategy 
might be the use of home-based (HB) training in combination with tele-monitoring 
guidance. It has been demonstrated that self-regulatory techniques create 
empowerment and perceived control and might have longer lasting effects on PA 
improvements. That is, individuals who develop their own PA plans are more likely 
to adhere to them than those who have a structured exercise plan imposed (7). A 
recent meta-analysis already demonstrated that HB cardiac rehabilitation in low to 
moderate-risk cardiac patients is safe, and has at least equal short-term clinical 
effects as CB cardiac rehabilitation (12, 13). Therefore, HB cardiac rehabilitation has 
been used more and more for certain patient groups to overcome the previous cited 
barriers and to promote patient self-efficacy for independent exercise. However, its 
effects on long-term physical fitness and activity levels as compared to CB programs 
remain inconclusive (13). 
To our knowledge, our study is the first to investigate clinical effects of HB cardiac 
rehabilitation with tele-monitoring guidance compared to CB cardiac rehabilitation in 
a randomized controlled design in patients with coronary artery disease (CAD) in the 
maintenance phase (WHO Phase III) following the supervised outpatient ambulatory 
rehabilitation program (Phase II) (14). The aim of this paper is to describe the 
rationale, design, and protocol of the Tele Rehabilitation in Coronary Heart disease 
study, TRiCH. 
OBJECTIVES AND HYPOTHESES 
The main objective of our trial is to compare the longer-term (=1 year) effects of a 3- 
month patient-tailored HB cardiac rehabilitation program with tele-monitoring 
guidance in CAD patients (phase III) with a supervised CB cardiac rehabilitation 
program program. The primary outcome measure is exercise capacity, measured as 
peak oxygen uptake (VO2P) at 12 months. VO2P was chosen as the primary 
endpoint because it is the most important predictor of cardiovascular morbidity and 
mortality in patients with CAD (15, 16). We hypothesize that patients randomized to 
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a HB training cardiac rehabilitation program with tele-monitoring guidance will 
demonstrate higher levels of PA at 1-year follow up, resulting in higher levels of 
physical fitness, compared to patients who have been enrolled to the CB cardiac 
rehabilitation program or control-group. 
Secondary outcome measures include determinants of exercise capacity (17, 18), 
i.e. PA, muscle function and endothelial function, health related quality of life 
(HRQoL) and traditional cardiovascular risk factors. 
The second objective of this study is to determine whether HB cardiac rehabilitation 
versus CB cardiac rehabilitation has a differential effect in improving physical fitness, 
and the secondary endpoints specified above, in the short-term (3 months) in CAD 
patients (phase III). It is hypothesized that the effect of HB cardiac rehabilitation will 
have a larger effect compared to advice only (control group), but that the effect will 
be similar to a CB cardiac rehabilitation. 
METHODS 
Trial design and participants 
The TRiCH study is planned as a randomized controlled clinical trial with a parallel 
group design at the University Hospital Leuven (Leuven, Belgium). Participants will 
be randomly assigned to one of the three groups: Home-based, Centre-based, or 
control group on a 1:1:1 basis. Primary and secondary outcome measures will be 
assessed at baseline, after the 3-month intervention period and at 12 months of 
follow-up. Participants will be 105 CAD patients who have been referred after acute 
myocardial infarction (AMI), percutaneous coronary intervention (PCI) or coronary 
artery bypass grafting (CABG) to the ambulatory rehabilitation program of the 
University Hospital Leuven and who have successfully completed this 3-month 
program (phase II). Inclusion and exclusion criteria of patients are shown in Table 1. 
The sample size calculation was based on our primary outcome, VO2P at 12 months. 
Assuming a difference of 4 ml/min/kg (effect size=0.65) between both exercise 
groups at follow-up, which has been shown earlier to be of clinical importance (19), 
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a total sample size of 105 patients is required with a power of 0.80 and a two-sided 
p-value of 0.05. 
The study protocol has been approved by the medical ethical committee of the UZ 
Leuven/ KU Leuven. Clinical trial registration: NCT02047942. 
Table 1. Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
 
Patients with CAD (post-PCI, post-MI, post-
CABG). 
 
Significant undercurrent illness last 6 weeks. 
Patients on optimal medical treatment and 
stable with regard to symptoms and 
pharmacotherapy for at least 6 weeks. 
Known severe ventricular arrhythmia with 
functional or prognostic significance; significant 
myocardial ischemia, hemodynamic 
deterioration or exercise-induced arrhythmia at 
screening or heart disease that limits exercise. 
Patients who have successfully completed the 
3-months ambulatory CB cardiac rehabilitation 
program. 
Co-morbidity that may significantly influence 
one-year prognosis any, active cancer. 
Patients over 40 and under 75 years old. Severe psychological and/or cognitive disorders 
that limit exercise. 
Access to internet facilities or PC at home  
 
Participant recruitment 
In a first step, eligible patients will be contacted in the last weeks of their in hospital 
ambulatory cardiac rehabilitation program (phase II) and will be provided oral 
information about the TRiCH study. Agreeing subjects will then receive written 
information material and are invited for a screening maximal cycle exercise test. If 
no exclusion criteria are present patients will be asked to give written informed 
consent, according to principles of Good Clinical Practice and the Declaration of 
Helsinki, before randomization. 
Randomization and Blinding 
A randomization schedule will be prepared by the principle investigator (AA) using a 
computer random generator (Random.org). After signing the informed consent and 
registration of the patient in the trial, the random allocation will be provided to the 
investigator following a phone call. It is inherently not possible to blind participants 
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and physiotherapists delivering the supervised training sessions as the control group 
is not receiving any intervention and the intervention groups will undergo their 
respective training programs in different environments (i.e home vs hospital setting). 
However, the investigator analysing the data will be blinded to group allocation. 
Intervention 
Patients randomized to CB cardiac rehabilitation will continue their training at the 
outpatient clinic of UZ Leuven under supervision of physiotherapists. Participants will 
be asked to perform three exercise sessions per week with duration of 90 minutes 
per session. Each session consists of endurance training (cycling, running, arm 
ergometry, rowing and dynamic callisthenics) followed by relaxation. The endurance 
exercise workload is individually controlled by clinical and heart rate monitoring. 
Training heart rate corresponded to 70-80% of heart rate reserve. Each patient 
spends on average 45 minutes at the training heart rate during each session. 
 The HB cardiac rehabilitation group will train the first three sessions under the 
supervision of the research group for acquaintance with the tele-monitoring system: 
i.e. heart rate monitors (Garmin Forerunner 210; Garmin), data uploading 
(http://connect.garmin.com/en-US/) as well as the intensity of exercise. After these 
sessions, patients will receive an individualized exercise prescription to be 
performed in the home environment. They will be recommended to exercise for at 
least 150 minutes a week (preferably 6 to 7 days/week) at an individually determined 
target heart rate zone corresponding to moderate intensity, i.e 70-80% of heart rate 
reserve (3, 20). All exercise data will be accessed by the research group on a weekly 
basis through the online web application. Patients in the HB cardiac rehabilitation 
group will receive weekly feedback by phone or e-mail. These contact moments will 
be used to check for adverse effects and injuries, discuss the exercise program, and 
discuss attendance/compliance and barriers to adherence/compliance if necessary. 
Patients randomized to the control group will only receive the usual advice given to 
patients at the end of the phase II ambulatory CR program, i.e. the recommendation 
to remain physically active. 
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After the 3-month intervention period all groups will be encouraged to continue 
exercising but no contact or feedback will be provided by the research group. 
Exercise Attendance and Compliance 
Attendance and compliance to the training programs will be established weekly for 
both intervention groups. Attendance will be defined by % of weekly volume 
(duration*frequency) of exercise attended by the participants; compliance will be 
defined by the % of exercise performed at the prescribed intensity. 
OUTCOME MEASURES 
All patients will be evaluated at baseline, immediately after the 3-month intervention, 
and at 1-year of follow-up. Evaluations include measurements of cardiorespiratory 
fitness (VO2P and submaximal measures of exercise), determinants of exercise 
capacity (PA, endothelial function, and muscle function), HRQoL and traditional 
cardiovascular risk factors. All measures will be completed by the same investigator 
at the same time of day for each individual patient. 
Primary outcome measure 
Cardiorespiratory fitness or exercise capacity. A maximal graded exercise test 
until volitional fatigue will be carried out using an individualized cycle (Ergometrics 
800 S, Ergometrics, Bitz, BadenWürttemberg, Germany) ergometer protocol (20 
watt+20 W/min or 10 watt+10 W/min) with gas analysis. Twelve-lead ECG will be 
recorded continuously and blood pressure will be measured every two minutes and 
at peak exercise. Breath-by-breath gas exchange measurements (Oxycon Pro TM 
Jaeger, Carefusion 234, GMbH Hoechberg, Germany) will allow on-line 
determination of ventilation (VE), oxygen uptake (VO2) and carbon dioxide 
production (VCO2) every 10 s. The test ends when cycling speed falls below 60 rpm 
or if the patient develops exercise-induced physiological signs that warrant a 
termination of the test (Depression of ST segment, significant arrhythmias, fall in 
systolic blood pressure >20mmHg from the highest value during test or hypertension 
>250mmHg, severe desaturation, loss of coordination, mental confusion, dizziness 
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or faintness) (21). After reaching maximal volitional fatigue, participants recuperate 
by cycling for another six minutes at 25 Watt. VO2P will be defined as the highest 
30-s average of VO2 at the end of the test. In addition, the following submaximal 
exercise parameters will be determined: ventilator anaerobic threshold (VAT), 
oxygen uptake efficiency slope (OUES), VeVCO2 slope, VO2/Load as well as the 
VO2-off time (22). 
Secondary outcomes 
Physical activity. PA will be objectively assessed with the Sensewear® Mini 
Armband (BodyMedia, Inc., Pittsburgh, PA, USA), a multisensory body monitor worn 
over the triceps muscle of the right arm. Patients will be asked to wear the device 24 
hours a day, except during water-based activities, for a total of 7 days (23). In 
addition, they will be asked to record their physical activities in a logbook. Data from 
these sensors will then be combined with gender, age, body weight and height to 
estimate energy expenditure and PA intensity, using algorithms developed by the 
manufacturer (SenseWear professional software, version 6.1). 
Muscle function. Oxygen uptake on-kinetics will be established on a separate day 
at least 48 hours after the maximal exercise test. Measuring oxygen uptake (VO2) 
kinetics quantifies the rate of increase in VO2 during the early phase of exercise 
providing information on muscle energetics, metabolic control and the determinants 
of the efficiency of skeletal muscle contraction. Slowed VO2 kinetics is associated 
with poor exercise performance (24). This measurement will start with a 3 minutes 
seated rest on the bike to obtain resting VO2 data. Next, subjects will be instructed 
to cycle at a rate of 70 rpm, against a resistance corresponding to 30% of peak load 
for 6 minutes. After 6 minutes of cycling, subjects remain seated on the bike for an 
additional 6 minutes, after which a second 6-minute exercise bout will be initiated 
(25). Subsequently, exercise-onset VO2 kinetics will be calculated according to 
previously published formula (25, 26). Following the on-kinetics protocol, maximal 
handgrip strength will be measured by means of a JAMAR grip strength 
dynamometer (Lafayette Instrument, USA) using a standardized protocol (27). This 
will be followed by testing of the maximal isometric knee extension strength and 
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endurance of the right quadriceps by isokinetic testing equipment (Biodex Medical 
Systems Inc., 840-000 System 4, New York, USA). Each subject will have to perform 
a total of three voluntary maximal isometric contractions (6s) at a 60° angle of the 
knee, with a 60-second rest period between each test; the highest value will be taken 
as the maximal isometric strength or peak torque (Nm). After 1 minute of recovery, 
patients will perform two bouts of 25 repetitive maximal isokinetic knee extensions 
at 180°/s, interspersed with 2-minute recovery intervals. Endurance will be 
calculated in each bout ([mean peak torque of the last 8 repetitions/mean peak 
torque of the first 8 repetitions] times by 100). Standardized verbal instructions and 
encouragements will be given (28). 
Endothelial Function. Brachial flow mediated dilation will be measured as 
previously described in our laboratory (29) and in agreement with international 
guidelines (30). Brachial artery images will be obtained using a Vivid 7 ultrasound 
system with a 12 MHz linear array transducer. The subject will be positioned supine 
with the right arm in a comfortable position for imaging the brachial artery. A blood 
pressure cuff will be placed proximal to the imaging transducer on the forearm and 
after a 10 minute period of supine rest, the cuff will be inflated to at least 200 mmHg 
or at least 50 mmHg over the systolic pressure for exactly 5 minutes. Longitudinal 
brachial artery images will be recorded during the final 30 seconds before the 
occlusion and for 150 seconds following cuff deflation. All data will be stored digital 
for later analysis. 
Traditional cardiovascular risk factors. Total cholesterol, high-density lipoprotein, 
low-density lipoprotein, triglycerides, plasma glucose and serum insulin will be 
analysed by the biochemical laboratory of UZ Leuven using standardized analytic 
methods on fasting blood samples. The HOMA index will be calculated as a measure 
of insulin resistance (31). Office blood pressure and heart rate will be measured in 
sitting position using an automatic device (OMRON M6 Comfort, Japan) after an 
initial rest of 5 minutes following the European Guidelines of Hypertension (32, 33). 
Blood pressure will be measured at least twice with 1-min intervals; if there is more 
than a 5 mmHg difference between the first and second reading; one extra reading 
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will be taken and office blood pressure will be defined as the mean of the last two 
measurements (33). Further, height and body mass will be measured in fasting state 
using a stadiometer and digital scale (Tefal PP6011) with patients barefoot and 
wearing light sportswear. Waist circumference will be measured at the approximate 
midpoint between the lower margin of the last palpable rib and the top of the iliac 
crest at the end of a normal expiration. Hip circumference will be assessed at the 
widest portion of the buttocks. Body mass will be measured to the nearest 0.1 kg, 
height and circumferences to the nearest 0.1 cm. Body mass index (weight/height²) 
and waist/hip ratio will be calculated. Body fat in % and Kg will be established by 
bioelectric impedance (Omron BF300, Japan). 
Health-related quality of life and sociodemographic data. Next to all the 
physiological parameters HRQoL will be assessed by means of the SF-36 health 
survey. This questionnaire will be used as a generic health status measure (34) and 
is composed of 36 questions and standardized response choices, organized into 
eight multi-item scales: physical functioning, role limitations due to physical health 
problems, bodily pain, general health perceptions, vitality, social functioning, role 
limitations due to emotional problems, and general mental health. Finally, 
sociodemographic data (e.g. age, gender, education, marital status) as well as data 
on medical and family history and use of medication will be obtained via 
questionnaires. 
STATISTICAL ANALYSES 
Microsoft Access will be used for database management and statistical analyses will 
be conducted using SAS 9.3 (SAS Institute, Inc, Cary, North Carolina, USA). All 
primary statistical analyses will be conducted on an intention-to-treat principle 
according to initial randomization. Missing data will be managed using the last 
observation carried forward method. As a proportion of dropouts may be expected, 
on-treatment analysis will give the physiological effect of training. Demographic 
characteristics and baseline data will be summarized using descriptive statistics and 
baseline comparability of the three groups will be examined. Multivariate analysis of 
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variance will be used to assess intra and intergroup differences and interactions in 
the parameters studied. A p-value<0.05 will be considered statistically significant. 
DISCUSSION 
Exercise-based cardiac rehabilitation is an important component of a comprehensive 
approach to cardiovascular disease patients. However, only a small percentage of 
cardiac patients are still active enough to obtain or even maintain health benefits one 
year after completion of an in hospital program (phase II). Tele-rehabilitation 
provides an alternative opportunity to improve the adherence to a physically active 
lifestyle. Namely, interventions that facilitate self-monitoring of behaviour change in 
daily life are recommended to improve activity behaviour (35). Moreover, the use of 
activity monitoring makes patients aware of their activity, which is likely needed for 
successful treatment effects (36). Therefore, we hypothesize that the use of Garmin 
Heart rate monitors and the Garmin online platform will make the patient more aware 
of his exercise behaviour. Moreover, as it allows real-time online supervision from a 
distant by an external health care provider who can give immediate feedback on the 
performed activity (duration, frequency but also intensity) and where needed 
motivation it is believed that this could have a more powerful influence on longer-
term activity behaviour and hence physical fitness and health compared to standard 
care or a prolonged supervised in hospital program. Here we describe the rationale, 
design and methods of the TRiCH study that will compare the longer-term effect of 
a three month tele-rehabilitation program with a 3-month prolonged supervised in 
hospital program and regular practice (CG). 
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ABSTRACT 
Background: Cardiac rehabilitation is an essential part of contemporary coronary 
heart disease management. However, patients exiting a centre-based CR program 
have difficulty retaining its benefits.  
Objective: We aimed to evaluate the added benefit of a home-based cardiac 
rehabilitation program with tele-monitoring guidance on physical fitness in patients 
with coronary artery disease (CAD) completing a phase II ambulatory cardiac 
rehabilitation program and to compare the effectiveness of this program in a 
prolonged centre-based cardiac rehabilitation intervention by means of a 
randomized controlled trial. 
Methods : Between February 2014 and August 2016, 90 CAD patients (unblinded, 
mean age, 61.2 (SD 7.6) years; the majority of participants (80/90, 89.0%) were 
males; mean height, 1.73 (SD 0.7) m; mean weight, 82.9 (SD 13) kg; mean body 
mass index, 27.5 (SD 3.4) kg/m2) who successfully completed a 3-month ambulatory 
cardiac rehabilitation program were randomly allocated to one of three groups: 
home-based (30), centre-based (30), or control group (30) on a 1:1:1 basis. Home-
based patients received a home-based exercise intervention with tele-monitoring 
guidance consisting of weekly emails or phone calls; centre-based patients 
continued the standard in-hospital cardiac rehabilitation, and control group patients 
received the usual care including the advice to remain physically active. All the 
patients underwent cardiopulmonary exercise testing for assessment of their peak 
oxygen uptake (VO2P) at baseline and after a 12-week intervention period. 
Secondary outcomes included physical activity behaviour, anthropometric 
characteristics, traditional cardiovascular risk factors, and quality of life. 
Results: Following 12 weeks of intervention, the increase in VO2P was larger in the 
CB (P = .03) and HB (P = .04) groups than in the control group. In addition, oxygen 
uptake at the first (P-interaction = .03) and second (P-interaction = .03) ventilatory 
thresholds increased significantly more in the home-based group than in the centre-
based group. No significant changes were observed in the secondary outcomes.  
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Conclusions: Adding a home-based exercise program with tele-monitoring guidance 
following completion of a phase II ambulatory cardiac rehabilitation program results 
in further improvement of physical fitness and is equally as effective as prolonging a 
centre-based cardiac rehabilitation in patients with CAD. 
Trial Registration: International Standard Randomized Controlled Trial Number 
(ISRCTN):   NCT02047942. 
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INTRODUCTION 
Cardiovascular diseases (CVD) remain the leading contributor to global premature 
mortality and morbidity. In Europe, more than 4 million people die from CVD every 
year, with more than 1.4 million dying before the age of 75 years (1). Today, 
secondary prevention of CVD, including CAD, by means of cardiac rehabilitation is 
considered a class IA recommendation by the European Society of Cardiology, 
American Heart Association, and American College of Cardiology (2). Cardiac 
rehabilitation is now recognized as an essential part of contemporary CAD 
management that has significantly contributed to the observed reduction in 
cardiovascular mortality and disability by facilitating the adoption of and adherence 
to healthy behaviours and promoting an active lifestyle (3). However, the majority of 
patients fail to achieve secondary prevention targets in the long term (4). Many 
patients receiving CB cardiac rehabilitation adopt healthier lifestyles but relapse into 
old habits when returning to everyday life. After completion of a structured, 
supervised, exercise-based cardiac rehabilitation program without any extended 
support or follow-up, the assumption, of both the participant and cardiac 
rehabilitation staff, is that the patient will be able to self-maintain these appropriate 
health behaviours and optimal CVD risk profile. Unfortunately, studies have shown 
that patients exiting CB cardiac rehabilitation have difficulty retaining the positive 
benefits derived from their participation (5). Moreover, previous reports indicate 
decreased exercise adherence and increased body weight and serum lipid levels as 
early as 6 months after cardiac rehabilitation (4, 6). 
Consequently, there is a need for innovative cardiac rehabilitation methods to 
increase long-term adherence to a physically active lifestyle that will result in more 
sustained effects on health-related physical fitness and cardiovascular health, thus, 
reducing morbidity and mortality (7). One attractive strategy is the use of HB exercise 
training in combination with tele-monitoring guidance. HB programs may overcome 
barriers associated with participation in a CB exercise program, and they have been 
shown to provide comparable long-term effects on mortality, recurrent coronary 
event risk, and cardiovascular risk factors in patients with CVD (8). This has been 
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attributed partly to the fact that HB interventions focus more on the development of 
self-regulatory techniques that create empowerment and perceived control, resulting 
in longer lasting effects on PA improvements (9). That is, individuals who develop 
their own PA plans are more likely to adhere to these plans than those who have a 
structured exercise plan imposed on them (9). The use of information and 
communication technology to augment HB programs also enables the provision of 
additional feedback, education, and counselling (8). 
A recent meta-analysis by Buckingham et al (10) found no significant differences in 
the short-term (<12 months) or long-term (>12 months) patient outcomes including 
exercise capacity, modifiable risk factors (blood pressure, blood lipid concentrations, 
and smoking), HRQoL, and cardiac events (mortality, coronary revascularization, 
and hospital readmissions) among patients participating in home-based or centre-
based phase II cardiac rehabilitation. However, there is little evidence about the 
added benefits of a HB exercise program for patients being discharged from CB 
cardiac rehabilitation compared with advice only. 
In this paper, we report on the secondary objective of the TeleRehabilitation in 
Coronary Heart disease (TRiCH) study. We aimed to investigate the short-term 
effect of a HB cardiac rehabilitation program with tele-monitoring guidance on 
physical fitness and other secondary outcomes in CHD patients following completion 
of a CB cardiac rehabilitation program. We also aimed to compare the effectiveness 
of this program with that of a prolonged CB cardiac rehabilitation program by means 
of a randomized controlled trial (NCT02047942). The longer-term results of the 
TRiCH study will be published in a second report. 
METHODS 
Study Design 
We conducted a randomized controlled trial using a three-arm, parallel group design 
among 90 low-to-moderate risk CAD patients completing a phase II cardiac 
rehabilitation program at the University Hospital Leuven (Belgium). The study 
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protocol was approved by the medical ethical committee of the UZ Leuven/KU 
Leuven. The protocol has been described in detail elsewhere (7). 
Patient Population and Randomization 
Patients were recruited between February 2014 and August 2016 at the University 
Hospital Leuven (Belgium). The eligible patients included men and women (aged 
between 40 and 75 years) with angiographically-documented CAD or previous 
myocardial infarction, on optimal medical treatment for the last 6 weeks, who 
successfully completed a supervised ambulatory cardiac rehabilitation program and 
who had access to a computer with Internet connection. The exclusion criteria 
included known clinically significant ventricular arrhythmia or exercise-induced 
arrhythmia at screening, myocardial ischemia, other cardiac diseases (valve disease 
with significant hemodynamic consequences, hypertrophic cardiomyopathy, etc), 
significant illness for the last 6 weeks, co-morbidity that might represent a significant 
influence on 1-year prognosis (eg, cancer), and co-morbidity that limits exercise 
testing and/or training. The criteria for ischemia on the electrocardiogram during 
exercise included horizontal or downsloping ST depression ≥1 mm at 80 ms after 
the J-point or any ST depression >1 mm at 80 ms after the J-point (11). The eligible 
patients were contacted in the last weeks of their in-hospital ambulatory cardiac 
rehabilitation program (phase II) and were provided verbal information about the 
TRiCH study. Agreeing patients subsequently received written information and were 
asked to provide written informed consent according to the principles of Good 
Clinical Practice and the Declaration of Helsinki. 
Procedures  
All the agreeing patients who had completed 40 sessions of their ambulatory cardiac 
rehabilitation program (phase II) were included and were subsequently randomized 
in a 1:1:1 ratio to one of three groups: HB group, CB group, or a CG (usual care) by 
means of a web-based random number generator. 
The HB cardiac rehabilitation group received training for the first three sessions 
under the supervision of the investigator. During this period, the patients received an 
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individualized aerobic exercise prescription recommending at least 150 min of 
exercise per week (preferably 6-7 days/week) at an individually determined target 
heart rate corresponding to a moderate intensity (ie, 70%-80% of heart rate reserve 
(HRR)) in their home environment during the 12-week intervention. Furthermore, this 
group received instructions on how to use the heart rate monitor (Garmin Forerunner 
210, Wichita USA) and how to upload their exercise data to the Garmin platform (12). 
This application was used to review the training data by both the patient and the 
investigator (13). Patients received feedback via phone or email once a week 
according to their preferences. These contact moments were used for the following 
purposes: 1) to check for adverse events and injuries, 2) to provide feedback on 
performed exercise during the preceding week, 3) to discuss the exercise program 
regarding duration and intensity, and 4) to discuss adherence and barriers to 
adherence if necessary. 
Patients randomized to CB cardiac rehabilitation continued their exercise program 
at the outpatient clinic of UZ Leuven under the direct supervision of physiotherapists. 
The patients were asked to perform three exercise sessions per week totalling 
approximately 150 min of endurance exercise. Each training session consisted of 
predominantly endurance training (2×7 min of cycling, 2×7 min of treadmill 
walking/running, 7 min of arm ergometry or rowing, and 2×7 min of dynamic 
calisthenics) and was followed by relaxation. The endurance exercise workload was 
individually controlled by heart rate monitoring, which was performed by palpation 
by the physiotherapist during the last minute of each round of exercise. Exercise 
load was adjusted to maintain target heart rate (70%-80% of the HRR). Patients 
randomized to the CG received usual care including the standard advice to remain 
physically active. 
Primary outcome measure 
Cardiorespiratory fitness or exercise capacity. Primary outcome was change in 
the exercise capacity following the intervention. Exercise capacity (defined as the 
maximum amount of physical exertion that a patient could sustain) (14) was 
determined at baseline and at the end of the intervention using a maximally graded 
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test on a bicycle with breath-by-breath respiratory gas analysis (Ergometrics 800S, 
Ergometrics, Bitz, Baden-Württemberg, Germany). Peak exercise capacity was 
defined as the 30-s average oxygen uptake (VO2) at the highest workload (7). 
Ventilatory thresholds (VTs), peak respiratory exchange ratio, and peak heart rate 
were also established (7). 
Secondary outcome measures 
Physical activity. Daily physical activity, measured using a Sensewear® Mini 
Armband (BodyMedia, Inc., Pittsburgh, PA, USA). Steps, sedentary time (duration 
of sedentary activity at an intensity of ≤1.5 metabolic equivalents of task [METs], 
min), active energy expenditure (physical activity at an intensity of ≥3 METs, kcal), 
and duration of moderate and vigorous physical activity (≥3 METs, min) were used 
in the analyses (15).  
Muscle function. Oxygen uptake on-kinetics were established at least 48 h after the 
maximal exercise test and was calculated algebraically and expressed as mean 
response time (7). Sitting-rising test (SRT), handgrip strength (JAMAR grip strength 
dynamometer), and quadriceps maximal isometric knee extension strength and 
endurance (Biodex Medical Systems Inc., 840-000 System 4, New York, USA) were 
obtained.  
Traditional cardiovascular risk factors. Anthropometric measures (body mass 
index, waist and hip circumference) and biochemical parameters of a fasting blood 
sample (glucose, total cholesterol, low-density lipoprotein [LDL] cholesterol, high-
density lipoprotein [HDL] cholesterol, and triglycerides). Additionally, homeostasis 
assessment model (HOMA) (16) index was calculated using the following formula: 
fasting plasma glucose (mmol/L) times fasting serum insulin (mU/L) divided by 22.5. 
Low HOMA-IR values indicated high insulin sensitivity, whereas high HOMA-IR 
values indicated low insulin sensitivity (insulin resistance). For this study, patients 
with HOMA-IR ≥ 3.8 were considered to be insulin resistant (17). 
Health-related quality of life. Finally, HRQoL was obtained by means of the 
standard version of the Short Form 36 (7). 
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STATISTICAL ANALYSES 
All data were expressed as mean ± SD or median, range, or percentages (for 
categorical variables). Statistical analyses were performed using SPSS (version 20; 
SPSS for windows; SPSS Inc., Chicago, IL). Shapiro–Wilk test was used to assess 
normality. At baseline, the groups were compared using one-way analysis of 
variance or chi-square tests. For follow-up data, a linear mixed modelling method 
was used to evaluate time, group, and time × group interaction effects. The analysis 
was complemented with a matrix syntax code including a least significant difference 
post-hoc test when a significant time × group interaction identified a group that 
significantly differed over time. An intention-to-treat analysis was performed on the 
primary outcome (peak VO2 [VO2P]), and on-treatment analysis was used for 
secondary outcomes. Spearman correlation coefficients (p) were calculated 
between VO2P and active energy expenditure and physical activity duration at 12 
weeks. A probability level of P ≤ 0.05 was considered significant. 
RESULTS 
A total of 90 CAD patients agreed to participate and were randomized to HB group 
(n = 30), CB group (n=30), and CG (n=30). Figure 4 shows the flow of patients 
throughout the study. Six patients, (4 men: CG, n=4; HB, n=2) dropped out during 
the 3-month intervention period. Reasons for dropout included loss of interest (CG, 
n=2; HB, n=2) and a new cardiac intervention (ie, percutaneous coronary 
intervention) (CG, n=2). No serious adverse events related to exercise occurred in 
any of the groups. 
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Figure 1. Flow of patients throughout the study. 
 
The basic characteristics of the study population are described in Table 2. The mean 
age of the participants was 61.4 (SD 7.3) years (range: 42-73 years). A total of 10 
(11.1%) women participated in the study, and patients were on average slightly 
overweight, 27.5 (SD 3.4 kg/m2). Overall, exercise capacity was normal, 101.1% (SD 
21.1) compared with reference values (18). Baseline characteristics were 
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comparable between the groups regarding physical characteristics, reason for 
referral, and pharmacological therapy. 
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Table 2. Baseline characteristics of patients. 
 
(Continued on next page) 
 
 
Characteristics HB  
n = 30 
CB  
n = 30 
CG  
n = 30 
General characteristics 
Age (years) ± SDg 58.6 ± 13 61.9 ± 7.3 61.7 ± 7.7 
Female (%)b 4 (13) 3 (10) 3 (10) 
% of Predicted peakVO2e 99.9 ± 23.1 99.3 ± 20.1 105.2 ± 20.2 
Reason for referral 
CABGc (%) 18 (60) 18 (60) 20 (67) 
PCId (%) 12 (40) 12 (40) 10 (33) 
Cardiovascular risk factors (%) 
Familial predisposition 12 (40) 8 (27) 13 (43) 
Hypertension 14 (47) 11 (37) 17 (57) 
Diabetes 12 (40) 8 (27) 4 (13) 
Dyslipidemia 15 (50) 17 (57) 19 (63) 
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Table 2. Baseline characteristics of patients. (Continued) 
 
g: Continuous variables are expressed as means ± SD, b: Dichotomous variables are expressed as numbers and percentages. c: coronary artery 
bypass graft, d: percutaneous coronary intervention, e: oxygen uptake. f: warfarine and clopidogrel. 
Characteristics HB  
n = 30 
CB  
n = 30 
CG  
n = 30 
Smoking 
Never-smoker 11 (37) 14 (47) 15 (50) 
Ex-smoker 16 (53) 15 (50) 15 (50) 
Current-smoker 3 (10) 1 (3) 0 
Medication 
Anti-hypertensivef 23 (77) 27 (90) 24 (80) 
Beta Blockers 21 (70) 23 (77) 25 (83) 
Statins 28 (93) 29 (97) 28 (93) 
Aspirin 29 (97) 27 (90) 29 (97) 
Anti-thrombotic 19 (63) 18 (60) 23 (77) 
Anti-arrhythmic 1 (3) 1 (3) 0 
Hypoglycemic 4 (13) 8 (27) 4 (13) 
Vasodilators 0 1 (3) 2 (7) 
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Primary outcome measure 
Changes in cardiorespiratory parameters are described in Table 3. As can be 
appreciated from peak respiratory exchange ratios (RER), participants in all three 
groups exerted a similar maximal effort at baseline and follow-up. The pattern of 
change in VO2P differed significantly over time among the three groups (group × 
time interaction, P = .04), with a larger improvement following HB (P = .03) and CB 
(P = .04) interventions than CG interventions. Group × time interactions were also 
established for O2 uptake at the first ventilatory threshold (VT1) (P-interaction = .03) 
and the second ventilatory threshold (VT2) (P-interaction = .03), with larger 
improvements in the HB group than in CG. 
 
 
 
 
Chapter 3 | 61 
 
Table 3. Changes in cardiorespiratory parameters at baseline and 3-month follow-up. 
Data are presented as mean ± SD. b: Respiratory exchange ratios, c: Heart rate, d: First ventilatory threshold, e: Second ventilatory threshold, m: 
Interaction.  a=P-interaction <0.05. 
 
 
HB 
n = 28 
CB 
n = 30 
CG 
n = 26 
P-Value 
 Baseline 3 Month  Baseline  3 Month  Baseline  3 Month  Time Group Interact.m 
VO2 Peak 
(mL•kg−1•min−1) 
26.7 ± 6.55 27.8 ± 6.8a 25.4 ± 7.32 26.7 ± 7.90a 26.6 ± 4.97 26.4 ± 5.42 .08 .69 .04, 
VT1d(mL•kg−1•mi
n−1) 
19.5 ± 1.07 21.5 ± 1.0a 19.5 ± 1.04 20.4 ± 1.04 19.9 ± 1.08 19.3 ± 1.11 .81 .06 .03, 
VT2e 
(mL•kg−1•min−1) 
24.9 ± 5.25 26.3 ± 6.9a 22.7 ± 6.95 24.2 ± 7.13 24.7 ± 5.08 22.9 ± 4.19 .41 .49 .03, 
Duration (s) 570 ± 136 587 ± 157 549 ± 133 552 ± 157 600 ± 126 579 ± 116 .89 .52 .23 
Peak HR (bpm)c 140 ± 18.8 139 ± 17.8 141 ± 21.5 140 ± 21.1 140 ± 18.9 140 ± 16.6 .75 .97 .95 
Peak load 
(Watts) 
198 ± 49 200 ± 54 191 ± 50 191 ± 54 206 ± 41 197 ± 38 .39 .67 .15 
Peak RERb 1.24 ± 0.89 1.21 ± 0.10 1.23 ± 0.80 1.24 ± 0.10 1.20 ± 0.8 1.20 ± 0.13 .47 .32 .36 
Borg 15.8 ± 1.16 15.8 ± 1.33 16.2 ± 1.04 16 ± 1.17 15.9 ± 1.05 16.2 ± 1.02 .87 .45 .38 
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Changes in daily PA are shown in Table 4. PA behavior remained constant after the 
intervention (P-time = .73). Ninety seven percent of patients met the international 
guidelines of 150 minutes or more of moderate PA per week (19). In addition, a 
significant increase in sedentary time in the CB group (P-interaction = .02) was 
found. No significant correlation between change in VO2P and change in active 
energy expenditure (Spearman p = -.14; P = .40) or change in PA duration 
(Spearman p = .09; P = .44) was found. However, a significant correlation between 
physical fitness and PA duration (Spearman p = .53; P < .001) at 12 weeks as well 
as with active energy expenditure (Spearman p = .37; P < .001) was found. 
As shown in table 5, isometric handgrip strength, isometric quadriceps strength and 
endurance as well as exercise onset oxygen uptake on kinetics remained stable 
during the follow-up. 
Further, cardiovascular risk factors (as can be seen in fig 5) and anthropometrics 
(Table 6) were similar between the groups at baseline and remained stable during 
the follow-up period, except for an increase in HOMA-index (P-time = .05) which was 
not different between the groups (P-interaction = .93).   
Finally, there were no significant changes in the overall score for HRQoL (P-
interaction = .57) as well as the physical (P-interaction = .50) and mental (P-
interaction = .85) composite score. (See Table 7 which shows HRQoL from baseline 
and follow-up evaluations). 
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Table 4. Changes in daily physical activity at baseline and 3 months follow up. 
 HB  
n = 24 
CB 
 n = 28 
CG  
n = 26 
P Value 
 Baseline 3Month Baseline 3Month Baseline 3Month Time Group Interact.m 
Steps/day 7896 
(2018-2554) 
6469 
(473-12828) 
7608 
(2474-3281) 
7065 
(489-4785) 
6419 
(2227-3181) 
6408 
(296-12041) 
.18 .56 .18 
Sedentary 
timec 
1039 
(688-1260) 
1032 
(790-1455) 
1005 
(122-1290) 
1094 
(857-1254)a 
1100 
(825-1355) 
1062 
(484-1402) 
.56 .43 .02 
Active EEb,d  1336 
(351-3217) 
1307 
(661-2246) 
1137 
(484-2539) 
1244 
(549-2745) 
1223 
(401-2253) 
1196 
(181-2510) 
.56 .40 .45 
PAh 
duratione  
145 
(34-299) 
141 
(51-259) 
146 
(28-417) 
134 
(29-366) 
114 
(30-311) 
114 
(6-382) 
.73 .27 .47 
Moderate 
PA durationf  
136 
(34-238) 
134 
(49-241) 
140 
(28-391) 
128 
(27-348) 
109 
(29-303) 
115 
(25-368) 
.57 .24 .62 
Vigorous PA 
durationg  
8 
(0-33) 
7 
(0-24) 
6 
(0-26) 
6 
(0-24) 
5 
(0-20) 
2 
(0-27) 
.50 .21 .59 
Data are presented as mean (range) .h: physical activity, b: energy expenditure, c: ≤ 1.5 METs; min/day, d: >3METs; kcal); e: >3METs; min/day, f: 
3-6 METs; min/day, g: >6 METs; min/day. a=P-interaction <0.05, m: Interaction. 
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Table 5. Changes in muscle strength and exercise-onset VO2.  
 HB 
n = 23 
CB 
n = 29 
CG 
n = 19 
P-Value 
 Baseline 3Month Baseline 3Month Baseline 3Month Time Group Interact m 
Muscle strength 
Handgrip 
strength (kg) 
43.1 ± 10.5 
 
44.7±12.3 
 
40.2 ± 8.6 
 
41.2 ± 8.3 
 
41.6 ± 8.3 
 
43.8 ± 9.3 
 
.99 .23 .23 
Isometric 
quadriceps 
(Nm) 
extension  
151.8   ± 28 164.1± 37 
 
150.5± 44.9 
 
155 ± 43.4 
 
148.7 ± 30 
 
148.8 ± 28.3 
 
.23 .47 .86 
Extension total 
work (180°/s 
(J))  
1614 ± 680  
 
1976± 718  
 
1758 ± 756 
 
1893±717 
 
1694 ± 796 
 
1906 ± 689 
 
.09 .94 .52 
 
Exercise-Onset VO2 kinetics 
Average 
MRT(s)  
45.5 ± 16.2 
 
39.8± 9.3  
 
38.7 ± 8.1 
 
40.8 ± 9.1 
 
39.8 ± 16.9 
 
43.6 ± 22 
 
.98 .64 .19 
Data are presented as mean ± SD. a: Kilograms b: Mean response time, c: Nm. d: 180°/s (J). m: Interaction.  
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Figure 2. Cardiovascular risk factors at baseline and follow-up. 
A  B  
C  D  
E  F   
Panel A: The intervention had no effect in total cholesterol levels in any group p interaction = .82), B: 
The HDL-Cholesterol did not change significantly in any group after the intervention (p interaction = 
.69). C: There was no significant change in the LDL-Cholesterol levels after 3-months (p interaction 
= .79), D: The triglycerides levels did not changed significantly from baseline to 3-months control in 
any group (p interaction = .27), E: Fasting glucose did not change significantly in any group during 
the intervention (p interaction = .71), F: Homa index did not show significant differences in any group 
after the intervention (p interaction = .93). No significant changes were found in cardiovascular risk 
factors. Dark gray column: HB group, White column: CB group, Light grey column: CG.
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Table 6. Outcomes at baseline and 3 months control in anthropometric parameters. 
 HB  
n = 28 
CB  
n = 30 
CG  
n = 26 
P-Value 
 Baseline 3Month Baseline 3Month Baseline 3Month Time Group Interactm 
Anthropometrics          
Weight(kg) 80.4 ± 10.3 79.8 ± 10.3 82.9 ± 15.3 82.4 ± 15 85 ± 12.7 84.1 ±11.9 .36 .22 .55 
BMIb (kg/m2) 26.6 ± 2.5 
 
26.4 ± 2.5 
 
27.8 ± 4 
 
27.6 ± 4.1 
 
28 ± 3.3 27.6 ± 2.6 .28 .21 .53 
Body fat % 26.8 ± 5.7 
 
26.5 ± 6.1 
 
29.5 ± 5.5 
 
28.4 ± 6.4 
 
29.5 ± 5.1 
 
28.8 ± 4.2 .16 .12 .60 
Waist 
Circumference 
(cm) 
96.8 ± 8.8 
 
95.2 ± 8.2 
 
98.7 ± 11.2 
 
99 ± 11.4 
 
99.5 ± 9.8 
 
99.6 ± 9.6 .81 .29 .11 
Hip 
circumference 
(cm) 
101.1 ± 5.9 
 
101 ± 5.4 
 
102.6 ± 7.4 
 
102.7 ± 7.6 
 
102.5 ± 4.1 102.1 ± 5.1 .31 .42 .82 
SBPd (mmHg) 125.3±15.6 
 
124.1± 13.9 
 
127.4 ± 15 
 
124.1 ± 13.8 
 
123.6 ± 13 
 
122.9 ± 14 .29 .75 .73 
DBPe (mmHg) 75.4 ± 9.5 
 
75.8 ± 9 
 
76 ± 8.3 
 
74.7 ± 8.2 
 
75.5 ± 8.9 
 
76.9 ± 7.9 
 
.81 .91 .37 
HRc (bpm) 56.8 ± 9.1 
 
56.4 ± 7.4 
 
57.1 ± 8.2 
 
57.7 ± 10.1 
 
56 ± 8.1 
 
56.7 ± 14 
 
.90 .68 .84 
Data are presented as mean ± SD. b: Body mass index, d: Systolic blood pressure, e: Diastolic blood pressure, c: Heart rate in rest, m: Interaction. 
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Table 7. Changes in Health related quality of life. 
 HB 
n = 28 
              CB 
            n = 30 
CG 
n = 26 
P-Value 
 Baseline 3Month Baseline 3Month Baseline 3Month Time Group Interact.m 
HRQoLb          
PFc  90±10.7 91.9±7.6 85.3±15.6 87.4±13.6 81.4±15.7 84.3±16.1 .19 .04 .49 
RPd 83.6±27.3 87.5±28.4 74.2±36.6 83.9±31.3 58 ± 41.4 61.4±38.9 .15 .00 .43 
BPe 84.2±13.7 80.9±17.7 82.5±19.2 83.8±23.3 72.7±23.3 77.6±23.2 .83 .11 .70 
GHf 74.2±13.1 75.2±18.7 75.7±13.6 72.4±22.9 64.2±16.6 71.5±19.1 .41 .17 .17 
VTg 72.8±13.9 71 ± 13.4 69.3±15.6 74.6±15.4 65.3±14.6 63.9 ± 20 .70 .06 .10 
SFh 87.6±16.7 90.6±16.5 86.6±17.3 89.1±15.7 83.7±18.2 89.5±17.5 .20 .81 .90 
REi 84.6± 27 86.8±22.8 84.5±33.3 86.8±29.1 86.2±30.2 84.7 ± 31 .73 .99 .79 
MHj 78.6±15.6 77.5±17.6 79.3±13.3 81.4 ± 15 78.2±15.6 76.6±21.1 .91 .72 .59 
PCSk 80.9±12.3 81.3±13.1 77.2±15.2 80.8±16.3 67,9±17.1 71.8±18.3 .008 .07 .50 
MCSl 79.8±13.7 80.2±13.5 77.5 ± 18 81.3±15.5 75.1±13.8 77.2±16.2 .06 .38 .85 
SF-36 82.2±13.3 82.6 ± 13 79.8±16.1 82.6±15.8 73.3±15.1 76.4±16.4 .07 .06 .57 
Data are presented as mean ± SD.  b: Health related quality of life. Scores of the domains of the 36-Item Short-Form of SF-36: 0= worst and 100= 
best score. c: Physical function, d: Role-physical function, e: Bodily pain, f: General health, g: Vitality, h: Social function, i: Role-emotional function. 
j: Mental health, k: Physical composite score, l: Mental composite score, m: Interaction.
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Training data 
Patients in the HB group performed an average of 2.5 (range: 12-60 sessions during 
12 weeks) sessions per week, while the CB group performed an average of 2.0 
sessions per week during the 12 weeks (range: 4-36 sessions during 12 weeks). 
Patients in the HB group exercised on average 164 minutes per week at an average 
intensity of 46.8% of HRR (76.7 minutes within prescribed zone). The CB group 
exercised on average 90 minutes per week at an average intensity of 61.2% of HRR. 
DISCUSSION 
The significant finding of our randomized controlled study is that a 3 month HB 
training intervention with tele-monitoring guidance results in a further improvement 
of exercise capacity (VO2P) in CHD patients who just completed a phase II 
ambulatory program and is as effective as a prolonged CB cardiac rehabilitation. The 
observed improvements of 1.30mL•kg-1•min-1 and 1.10mL•kg-1•min-1 in VO2P  for CB 
and HB groups respectively, are likely to be clinically relevant as it has been shown 
earlier that 1mL•kg-1•min-1 increase in exercise capacity is associated with a 10% 
reduction in cardiovascular mortality (20).  As such, our results support the added 
value of a structured continued rehabilitation program. 
There are only few studies in the literature that have investigated the effectiveness 
of a HB tele-monitored phase III CR program, starting immediately after completion 
of a phase II CB cardiac rehabilitation program. A small proof of concept study by 
Brubaker et al (5) randomly assigned 31 patients to HB, CB or standard care.  In line 
with our results, they found that a HB program was as effective as the CB program 
at improving/maintaining oxygen consumption nine months after exiting a cardiac 
rehabilitation program.  In the Telerehab III trial (21), 140 patients were randomized 
to a tele-rehabilitation program in addition to conventional cardiac rehabilitation or 
conventional cardiac rehabilitation alone. This study also reported that a 6-month 
patient-specific comprehensive tele-rehabilitation program initiated six weeks after 
the start of ambulatory rehabilitation leads to a bigger improvement in VO2P and 
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confirmed our results of a lack of an additional weight loss, blood pressure reduction 
or lipid profile improvement and/or glycaemic control. 
In the last decade, several meta-analyses have been published demonstrating the 
effectiveness of HB programs for CHD patients implemented as a phase II cardiac 
rehabilitation program (22-24). Although the increase in VO2P of 4 to 5% in our phase 
III CB and HB groups is less than what is seen in previous phase II programs, this is 
still of clinical relevance as the purpose of phase III (maintenance phase) of cardiac 
rehabilitation is to preserve or if possible enhance the health benefits gained in 
phase II. Our results further show that even although patients in the HB group only 
exercised 75 minutes per week at the prescribed intensity and the average intensity 
was below the recommended thresholds, patients were still able to further increase 
their exercise capacity when compared to patients in the CG that received the advice 
the maintain a physically active lifestyle. This is in line with meta-analytic results of 
Swain and Franklin (25), demonstrating that in healthy individuals  with a mean 
baseline VO2max <40 mL•kg-1•min-1 there is no clear minimal intensity threshold to 
increase their aerobic capacity and patients can already show improvements when 
exercising at intensity of 40% of HRR.  Yet, there is abundant evidence that larger 
effects on health and fitness are established when individuals/patients exercise at 
higher intensities and larger volumes (26). 
With regard to PA, Ayabe et al (27), reported that 6500-8500 steps/day should be 
considered as the minimal and optimal goal of PA for secondary prevention of 
cardiovascular disease. With the number of steps ranging between 7612 steps (HB) 
and 7700 steps (CB our patients are within this target zone; whereas patients in the 
CG (5566) do not seems to reach this.  However, we were not able to promote an 
additional increase in the number of daily steps. These results are in line with 
previous publications that showed how exercise interventions focused on physical 
fitness improvement in cardiac patients do not have effect on the improvement of PA 
(21, 28, 29). 
We observed however a small but significant increase in sedentary time in the entre-
based group. Evidence suggests that those participating in exercise-focused 
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interventions are not likely to reduce their sedentary time by a meaningful amount 
(30).  King et al.,(31) explained this behaviour as a compensatory effect for exercise. 
That is, the simple fact of enrolling in a supervised exercise program might reduce 
PA levels throughout the rest of the day. This compensatory effect acts in different 
ways – by promoting adjustments in energy expenditure in order to save energy or 
recover from the exercise training,  consequently increasing the sedentary time (32). 
Growing evidence suggest that prolonged sedentary behaviour can affect 
cardiovascular and all-cause mortality risk independent of PA (33). Probably, 
recommendations on sedentary behaviour might be included in cardiac rehabilitation 
programs, given the current state of the evidence (30). 
Small improvements in weight reduction and body composition as well as in blood 
pressure were observed post-intervention, although this did not reach significance. 
This is consistent with the findings in the Telerehab III study (21).  According to 
Frederix et al, digital health interventions seem to be able to improve cardiovascular 
risk factors in primary prevention, but not in secondary prevention programs (21). 
Furthermore, we might hypothesize that when the pharmacological management of 
the groups is close to optimal, like in our patients, then the incremental benefit of 
secondary prevention programs over usual care may be very small (34). 
One of the main objectives of cardiac rehabilitation is to optimize patients’ physical 
functionality as a means to improve quality of life. In our study, no effects of our 
interventions on different HRQoL domains could be found. Contrary to our results, 
Smith et al (35) found clinically and statistically significant improvements in HRQoL 
in their home group after a six month intervention compared to their hospital group. 
The author considered that six months of cardiac rehabilitation, regardless of 
location, was associated with improvements in physical HRQoL. Thus, it is possible 
that with a longer intervention for both groups some differences could have been 
obtained in our study. 
One area that is not commonly considered in cardiac rehabilitation is the functional 
status or abilities of the patients. The typical patient in cardiac rehabilitation is over 
the age of 60, presents with multiple cardiovascular risk factors, such as inactivity 
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and obesity, and is recovering from a recent cardiac event. All these factors can lead 
to deficits in balance, mobility and function. Sumide et al., found that musculoskeletal 
fitness and flexibility, measured by the SRT, was a significant predictor of mortality 
in 51-80 year-old participants (36). In the present study no significant difference was 
present in the SRT between the groups (P = .36). Our results are in line with previous 
studies (Oerkild et al) (37). As for components of muscular fitness, Mroszczyk et al 
(38) and Thomaes et al (39) found increased HG strength in patients following three 
months of a (predominantly aerobic exercise training) cardiac rehabilitation program. 
In our study though, no changes were observed after 12 weeks of intervention. It is 
possible that the largest gains in HG strength appear during phase II of cardiac 
rehabilitation, while our intervention targeted Phase III patients. In addition, we found 
no significant difference in knee extension strength or resistance after 3 months of 
HB or CB training which could be explained by the focus on aerobic training during 
the intervention. These results are also consistent with previous studies (40, 41).  
Conraads et al, collected muscle strength data in 75 CAD patients before and after 
12 weeks of an AIT or ACT cardiac rehabilitation program finding that muscle 
strength did not improve. The author considered as possible causes the use of 
statins that has been associated with negative side effects on the muscles. In our 
study 94% of the patients were treated with statins, although insufficient evidence 
exists to prove that statins really affect muscle strength (42). Currently, there is very 
limited evidence regarding the effects of tele-rehabilitation on muscle strength and 
more research is needed (43). 
Finally, while short-term changes are of interest, it is important to establish whether 
the benefits are maintained in time, thus further research should focus on the long 
term effects of HB cardiac rehabilitation with tele-monitoring guidance. 
Limitations 
Our study should be interpreted within the context of its limitations.  First of all, next 
to PA training, cardiac rehabilitation includes other important core components such 
as nutritional counselling, risk factor management and psychosocial management. 
Although, PA training comprises 30-50% (up to >70%) of all cardiac rehabilitation 
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activities. it should be acknowledged that this study evaluated the effect of  PA tele-
monitoring rather than tele-rehabilitation (3).   Second, heart rate monitors were only 
used in the HB group as we opted to not change the traditional CB program where 
heart rate is measured by palpation by physiotherapists.  As such, we were not able 
to precisely define the exact number of minutes patients spend within the prescribed 
training zone.   
Another limitation in this study is the lack of blinding of test personnel. However, as 
the main outcome measure was VO2P, the effort of the participants can be 
objectively quantified by means of the respiratory exchange ratio (RER) and 
subjectively by means of the Borg scale (44). The study, as most randomized 
controlled trials, had missing outcome data. In muscle strength due to technical 
problems 19 values were missing completely at random and for PA, in 12 patients 
the data was incomplete and thus excluded.  
CONCLUSION 
The results of our study show that HB cardiac rehabilitation with tele-monitoring 
guidance can be an effective alternative to CB cardiac rehabilitation for further 
improving exercise capacity following phase II cardiac rehabilitation in CHD patients.   
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ABSTRACT 
Background: Exercise and PA are an essential part of contemporary CAD 
management. However, evidence shows that patients experience clear difficulties in 
maintaining a physically active lifestyle following completion of a structured and 
supervised phase II exercise-based cardiac rehabilitation program. HB interventions 
have shown to enhance a patient’s self-efficacy and might facilitate the lifelong 
uptake of a physically active lifestyle. Yet, data on the long-term effectiveness of HB 
exercise training on PA and exercise capacity are scarce. 
Objective: The main purpose of the TeleRehabilitation in Coronary Heart disease 
(TRiCH) study was to compare the long-term effects of the implementation of a short 
HB phase III exercise program with tele-monitoring guidance to a prolonged CB 
phase III program in patients with CAD. Primary outcome measure was exercise 
capacity. Secondary outcome measures included PA behaviour, cardiovascular risk 
profile and health related quality of life.  
Methods: Ninety CAD patients (80 male) were randomized to three months of HB 
(=30), CB (=30) or a control group (CG) (=30) on a 1:1:1 basis after completion of 
their phase II ambulatory cardiac rehabilitation program. Outcome measures were 
assessed at discharge of the phase II program and after one year.  
Results: Eighty patients (72 (91%) men and mean age 62.6 years old) completed 
the one-year follow-up measurements. Exercise capacity (VO2P), cardiovascular 
risk factors and HRQoL were preserved in all three groups (p-time >0.05 for all), 
irrespective of the intervention (p-interaction >0.05 for all). Eighty five percent of 
patients met the international guidelines for PA (p-time < 0.05). No interaction effect 
was found for PA (steps, amount of active time, and amount of sedentary time) over 
the one-year period after discharge of a phase II program.    
Conclusion: Overall, exercise capacity remained stable during one year following 
phase II cardiac rehabilitation. Our HB exercise intervention was as effective as CB 
and did not result in higher levels of exercise capacity and PA compared to the other 
two interventions. 
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INTRODUCTION 
Cardiac rehabilitation contributes significantly toward the care of cardiovascular 
disease patients (1), and is nowadays considered as a class IA recommendation by 
all international guidelines (2, 3). Cardiac rehabilitation is a complex multidisciplinary 
intervention that comprises different therapies: i.e. risk factor education and 
modification, health behaviour change, psychological support, vocational support 
and nutritional counselling. These interventions target risk factors for CAD(4),  and 
have PAand exercise as their core accounting for 30-70% of the total programme. 
Among patients with established CAD, participation in an exercise-based cardiac 
rehabilitation programme provides major health benefits including reduced risk for 
cardiovascular mortality and hospitalization (and associated health care costs) and 
improvements in health related quality of life (HRQoL) (5).  
Nevertheless, long-term adherence to a healthy active lifestyle remains the biggest 
challenge for these patients (6). Evidence shows that PA levels decline after cardiac 
rehabilitation completion with as few as 28% of patients maintaining the 
recommended levels at 12 months of usual care (7). Previously, Hansen et al (8), 
showed that only 27% of patients that participated in a CB phase II programme 
adhered to the minimal PA level (9) that is required for significant health benefits at 
18 months of follow-up. This is especially worrisome since PA might underlie the 
maintenance of exercise capacity (VO2P) which when compared with other known 
cardiovascular risk factors, is the strongest predictor of mortality among CAD 
patients (10).   
In Belgium, 15-20% of patients participate in an ambulatory cardiac rehabilitation  
programme (phase II), whereas only 5% participates in a long-term phase III 
maintenance intervention (11). Since it is often easier to integrate an exercise routine 
into the home and community environment (12), the use of HB cardiac rehabilitation 
carries the potential to improve compliance to an active lifestyle compared to CB 
cardiac rehabilitation in the long-term post-hospitalization (12).  
The technological advances of the last decade have allowed moving away from the 
hospital setting towards the use of exercise training in the patients’ home. Amongst 
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others, tele-rehabilitation involves the guidance and monitoring of the patient from a 
distance and provision of personalized feedback on a regular base. Earlier meta-
analytic data already showed that HB rehabilitation could be an alternative for 
supervised cardiac rehabilitation for promoting maintenance of exercise capacity in 
the short-term (13). However, the long-term effects of HB have not been widely 
studied.  Recently Claes et al. (14) identified respectively, three and seven studies 
evaluating PA and exercise capacity at least one year following HB cardiac 
rehabilitation (14). Small, though clinically none significant, effect sizes for exercise 
capacity were found in favour of HB cardiac rehabilitation compared to CB cardiac 
rehabilitation in the longer-term with similar effects on PA behaviour. Moreover, none 
of these studies used objective tools to assess PA.    
Given the limited data available, the objective of the current report was to compare 
the long-term effects (i.e.one year after completion of an ambulatory phase II cardiac 
rehabilitation programme) of a 12-week HB program or a 12-week prolonged CB 
program on exercise capacity by objectively measuring PA behaviour in CAD 
patients. We hypothesized that patients enrolled in the HB group would show less 
decrease in peak oxygen consumption (VO2P) and higher levels in PA compared to 
patients in the CB and CG group.   
METHODS 
Study design and Population 
The TRiCH study is a randomized controlled clinical trial designed to investigate the 
long-term effect of a HB exercise intervention with tele-monitoring guidance on 
exercise capacity, PA and other secondary outcomes in CAD patients after 
discharge from a phase II cardiac rehabilitation program. A detailed description of 
the experimental design (15), recruitment procedure and eligibility criteria as well as 
the short-term results (16) have been reported elsewhere. The study protocol was 
approved by the medical ethical committee of the UZ Leuven/ KU Leuven and all 
patients provided written informed consent. The TRiCH study was registered in 
ClinicalTrials.gov database: NCT02047942.  
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In summary, ninety CAD patients who successfully completed a supervised and 
structured phase II cardiac rehabilitation program were randomized on a 1:1:1 basis 
to HB, prolonged CB or CG for 12 weeks. As described previously (15), the HB group 
trained the first three sessions under supervision of the investigator after which they 
received an individualized aerobic endurance exercise prescription recommending 
them to exercise for at least 150 minutes a week at a target heart rate of 70-80% of 
HRR at home for 12 weeks. Patients were asked to log all exercise data by means 
of a Garmin Forerunner (Garmin Forerunner 210, Wichita USA) and to upload the 
data on the online web application (https://connect.garmin.com/nl-NL/) for review by 
the investigators (17). Once a week, patients received feedback by phone or e-mail.  
Patients randomized to CB continued their training on an ambulatory base at the 
outpatient clinic of UZ Leuven under direct supervision of physical therapists. This 
intervention included three weekly sessions, consisting of approximately 45 minutes 
of endurance training at 70-80% of HRR followed by relaxation. The CG was advised 
to maintain a physically active lifestyle and was invited for the follow-up visits at 12 
weeks and one-year.  Following completion of the 12-week intervention, all groups 
were encouraged to continue exercising but no contact or feedback was provided 
during the subsequent nine months.  
Primary outcome measure 
Cardiorespiratory fitness or exercise capacity. The primary outcome, exercise 
capacity, was determined as VO2P assessed by a maximal graded test on a bicycle 
until volitional exhaustion with breath-by-breath respiratory gas analysis 
(Ergometrics 800S, Ergometrics, Bitz, Baden-Württemberg, Germany) and 
continuous 12-lead electrocardiogram. The test started at 10 or 20 W and was 
increased with 10 or 20 W/minute. We defined VO2P as the 30 seconds average 
oxygen uptake at the highest workload (15). Individual VO2P results were compared 
with predicted reference values of Wasserman (18). Additionally, we measured peak 
heart rate, calculated peak respiratory exchange ratio and determined both 
ventilatory thresholds (VT) (15).  
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Secondary outcome measures 
Physical activity. PA was measured with a Sensewear® Mini Armband 
(BodyMedia, Inc., Pittsburgh, PA, USA) worn on the non-dominant arm for a 
minimum of five consecutive days. Steps, sedentary time (duration of sedentary 
activity at an intensity of ≤1.5 metabolic equivalents of task [METs]; minutes), 
duration of light intensity physical activity (≥1.5 and ≤3 METs; minutes) and duration 
of moderate and vigorous PA (≥3 METs; minutes) were used in the analyses (19). 
Patients meeting the international guidelines of minimum 150 minutes of moderate 
PA or 60 minutes of vigorous activity at the one year follow up were labeled as 
‘physically active’ (9).  A valid day was considered if at least 1368 minutes of data 
was obtained (95% of a 24 hour period (20). 
Muscle function. Sit and rising test (21), handgrip strength (JAMAR grip strength 
dynamometer) (22, 23) and quadriceps maximal isometric knee extension strength 
and endurance (Biodex Medical Systems Inc., 840-000 System 4, New York, USA) 
were also obtained (23).  
Traditional cardiovascular risk factors. Further, we measured the following 
traditional cardiovascular risk factors including anthropometric characteristics (body 
mass index, waist and hip circumference), blood pressure and biochemical analysis 
of a fasting blood sample (glucose, total cholesterol, LDL-cholesterol, HDL-
cholesterol and triglycerides).  
Health-related quality of life. Finally, the SF 36 was used to assess HRQoL (15).   
STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS (version 20; SPSS for windows; 
SPSS Inc., Chicago, IL). The current report compares the data obtained at discharge 
of the phase II cardiac rehabilitation program (= baseline) and after one year follow-
up between the different groups. The Shapiro-Wilk test was used to assess normality 
of distributions. Continuous variables are reported as means ± standard deviation 
(SD) or median, categorical data as numbers and percentages.  One-way analysis 
of variance (ANOVA) and chi-square tests were used to analyse differences in 
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demographic and clinical data between groups at baseline. For follow-up data, a 
linear mixed modelling method was used to evaluate time, group and time x group 
interaction effects. Spearman correlation coefficients (p) were calculated between 
VO2P and PA characteristics. A two-tailed P ≤0.05 was considered statistically 
significant. 
RESULTS 
Figure 6 shows the flow throughout the study. Ninety one percent or 80 patients 
completed the one year follow up measurements. Four patients (3 men) from the HB 
group, one patient from the CB group (1 men) and five patients (4 men) from the CG 
group dropped out. At baseline, groups were equal with regard to demographic and 
clinical characteristics, reason for referral and pharmacological treatment (Table 8). 
Demographic characteristics of patients that dropped out were not different from the 
other participants.  
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Figure 6. Flow of patients throughout the study. 
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Table 8. Baseline characteristics of patients. 
(Continued on next page) 
 
 
 
 
Characteristics HB  
n = 26 
CB 
n = 29 
CG  
n = 25 
Age (years) ± SDg 62.2 ± 7.1 62.0 ± 7.4 63.7 ± 7.4 
Female (%)b 3 (12) 3  (10) 2 (8) 
Reason for referral 
CABGc (%) 15 (58) 17 (59) 16 (64) 
PCId (%) 11 (42) 12 (41) 19 (36) 
Cardiovascular risk factors (%) 
Familial predisposition 11 (42) 8 (27) 9 (36) 
Hypertension 10 (38) 10 (34) 13 (52) 
Diabetes 2 (8) 7 (24) 3 (12) 
Dyslipidemia 13 (50) 16 (55) 14 (56) 
86 | Chapter 4 
 
Table 8. Baseline characteristics of patients. (Continued) 
 
g: Continuous variables are expressed as means ± SD, b: Dichotomous variables are expressed as numbers and percentages. c: coronary artery 
bypass graft, d: percutaneous coronary intervention, f: warfarine and clopidogrel. 
Characteristics HB  
n = 26 
CB 
n = 29 
CG  
n = 25 
Smoking 
Never-smoker 11 (42) 14 (48) 13 (52) 
Ex-smoker 12 (12) 14 (48) 12 (48) 
Current-smoker 3 (46) 1 (4) 0 
Medication 
Anti-hypertensivef 19 (73) 26 (90) 19 (76) 
Beta Blockers 17 (65) 22 (76) 20 (80) 
Statins 24 (92) 28 (97) 23 (92) 
Aspirin 24 (92) 27 (93) 24 (96) 
Anti-thrombotic 18 (69) 17 (59) 19 (76) 
Anti-arrhythmic 1 (4) 1 (3) 0 
Hypoglycaemic 3 (12) 8 (28) 4 (16) 
Vasodilators 0 1 (3) 2 (8) 
Chapter 4 | 87 
 
Primary outcome measure 
As can be appreciated from the respiratory exchange ratios (RER) and the BORG 
score, participants in all three groups performed a comparable maximal effort at the 
end of phase II and at one year follow-up (Table 9).  Overall VO2P (mL•kg-1•min-1) 
and the maximal test duration remained stable over time whatever the group, with 
subtle though non-significant decreases in the CB and CG group. In line, VT1 
insignificantly decreased in the CB and CG group, whereas it remained stable in the 
HB.  Difference in responses between groups did however not reach statistical 
significance (P-interaction = >.05 for all). After one year, 12 patients (46%) from the 
HB group decreased their VO2P in more than 1 mL•kg-1•min-1, as well as 12 patients 
(41%) in the CB group and 14 (56%) of the CG group. 
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Table 9. Changes on primary outcome and other respiratory parameters during the study. 
Data are presented as mean ± SD. b: Respiratory exchange ratios, c: Heart rate, d: First ventilatory threshold, e: Second ventilatory threshold, m: 
Interaction.  a=P-interaction <0.05. 
 
 
HB 
n = 26 
CB 
n = 29 
CG 
n = 25 
P-Value 
 Baseline 1 Year  Baseline  1 Year  Baseline  1 Year  Time Group Interact.m 
VO2 Peak 
(mL•kg−1•min−1) 
26.7 ± 6.55 27.1 ± 6.5 25.4 ± 7.3 24.5 ± 6.4 26.6 ± 4.97 26.2 ± 7.6 .53 .54 .72 
VO2 Peak 
(ml/min) 
 
2140 ± 599 2227 ± 670 2090 ± 601 2004 ± 508 2300 ± 449 2251 ± 641 .73 .32 .36 
VT1d(mL•kg−1•mi
n−1) 
19.5 ± 4.9 20.7 ± 6 19.5 ± 6.4 18.7 ± 5.8 20 ± 4.9 19.8 ± 6.3 .99 .80 .13 
VT2e 
(mL•kg−1•min−1) 
24.9 ± 5.2 24.8 ± 6.2 22.7 ± 6.9 22.3 ± 6.1 23.8 ± 5.8 24.3 ± 5.4 .41 .37 .62 
Peak HR (bpm)c 140 ± 18 142 ± 15 141 ± 21 141 ± 20 140 ± 18 146 ± 20 .12 .87 .47 
Peak RERb 1.24 ± 0.8 1.20 ± 0.9 1.23 ± 0.8 1.22 ± 0.8 1.18 ± 0.1 1.21 ± 0.1 .22 .48 .07 
Borg 16 ± 1 15.8 ± 1.2 16.2 ± 1.1 16.1 ± 1.1 15.9 ± 1 16.1 ± 0.9 .91 .56 .42 
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Secondary outcome measures  
Figure 7 shows PA data of the three groups at the end of cardiac rehabilitation and 
at one year of follow-up.  Overall, 96.6% of the population met the international 
guidelines of 150 minutes or more of moderate PA per week at discharge from phase 
II cardiac rehabilitation.  At one-year of follow-up, the number of patients fulfilling 
these guidelines had decreased to 85% (p = .1). There were no differences across 
groups (P-group = .12). PA, by measurement of average steps per day, trended up 
in HB group from a median of 7896 (2018 - 12554) at baseline to 8002 (1612 – 
17237) at follow-up, and down in the other groups although showing no significant 
interaction (P-interaction = .75). Although the time spent in light physical activity 
trended up in the three groups, it showed no significant interaction (P-interaction = 
.72). The time spent in moderate to vigorous physical activity, defined as PA with an 
intensity of > 3 METS, was lower at 12 months of follow-up compared to baseline 
(P-time = .01). However, the decrease was similar in the three groups (P-interaction 
= .95).   As shown in Table 10, the improvement in isometric quadriceps extension, 
isokinetic total work and handgrip strength reached statistical significance (P-time = 
<.001) without significant differences among groups (P-interaction = >.05).   
On the other hand, body weight (P-time = .14) increased over time with no change 
in other measures of body composition (Table 11).  Systolic blood pressure remained 
stable (P-time = .36), whereas a small though significant increase was observed for 
diastolic blood pressure from baseline to follow-up (P-time = .05).  A tendency 
towards higher total cholesterol and LDL values was observed among all three 
groups (p-time = 0.09 and .16 respectively). Other cardiovascular risk factors did not 
change significantly over the one-year period.  Further, there were no interactions 
with the group for any of these parameters (P-interaction = > .05 for all).   
Finally, all groups maintained high scores for all HRQoL parameters at one year of 
follow-up, the interaction in the overall score as well as the sub scores were not 
significant between the groups (P-interaction = .70) as can be seen in Figure 8. 
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Figure 8. Daily physical activity at baseline and follow-up. 
 
Data are presented as percentage, mean ± SE. Panel A: PA guidelines (>150 min/week), B: The 
intervention had no effect in steps/day in any group, C: Sedentary behaviour = ≤ 1.5 METs; min/day, 
D: Physical activity duration = >3METs; min/day, HB: Home-based group, CB: Centre-based group, 
CG: Control group. White column: Baseline, Dark gray column: one year follow-up. 
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Table 10. Changes in strength during the study. 
 HB 
n = 16 
CB 
n = 27 
CG 
n = 18 
P-Value 
 Baseline 1 Year Baseline 1 Year Baseline 1 Year Time Group Interact m 
Muscle strength 
Handgrip 
strength (kg)  
43.1 ± 10 45.7 ± 13 40.2 ± 8.6 42.6 ± 8.9 41.6 ± 8.3 47.2 ± 9.7 .00 .43 .49 
Isometric 
quadriceps 
extension (Nm) 
151.8 ± 28 168.9 ± 31 150.2 ± 45 157.7 ± 40 148.7 ± 30 163.7 ± 37 .00 .72 .33 
Extension total 
work (180°/s 
(J)) 
1614 ± 680 1155 ± 272 1758 ± 756 1117 ± 293 1695 ± 796 1142 ± 254 .00 .86 .77 
Sit and Rising 
Test 
7.56 ± 1.8 7.93 ± 1.3 7.44 ± 1.5 7.42 ± 1.3 7.47 ± 1.1 7.30 ± 1.3 .39 .53 .22 
Data are presented as mean ± SD. m: Interaction. 
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Table 11. Cardiovascular risk factors and anthropometrics characteristics during the study. 
 HB  
n = 28 
CB  
n = 30 
Control  
n = 26 
P-Value 
 Baseline 3Month Baseline 3Month Baseline 3Month Time Group Interactm 
Anthropometrics          
Weight(kg) 80.4 ± 10 81.5 ± 10 82.9 ± 15 82.9 ± 10 85 ± 12 85.6 ± 12 .14 .45 .51 
BMIb (kg/m2) 26.6 ± 2.5 26.9 ± 2.6 27.8 ± 4 27.8 ± 4.3 28 ± 3.3 28.2 ± 2.9 .12 .31 .62 
Waist 
Circumference 
(cm) 
96.8 ± 8.8 97.1 ± 9.1 98.7 ± 11 99.7 ± 11 99.5 ± 9.8 100.3 ± 10 .36 .51 .91 
Hip 
circumference 
(cm) 
101.1 ± 5 101.3 ± 5 103 ± 7.4 102.5 ± 7.8 102.9 ± 4 102 ± 4 .20 .60 .43 
Body fat (Kg) 22.4 ± 4.7 23.5 ± 4.3 24.1 ± 7 24.4 ± 7.6 25.7 ± 6 25.6 ± 5 .14 .31 .25 
Body fat % 26.8 ± 5.7 28.2 ± 4.1 29.5 ± 5 29.1 ± 6.3 29.5 ± 5 29.4 ± 4.7 .32 .29 .06 
Data are presented as mean ± SD. B: Body mass index, m: Interaction. (Continued on next page) 
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Table 11. Cardiovascular risk factors and anthropometrics characteristics during the study (Continued). 
 HB  
n = 28 
CB  
n = 30 
Control  
n = 26 
P-Value 
 Baseline 3Month Baseline 3Month Baseline 3Month Time Group Interactm 
Cardiovascular risk factors         
SBPd (mmHg) 124.6 ± 15 125.3 ± 15 127.3 ± 15 122.8 ± 15 124.2 ± 13 123.8 ± 17 .36 .95 .32 
DBPe (mmHg) 75.4 ± 9.7 77.6 ± 11 75.6 ± 8 74.9 ± 8 76.1 ± 8 80.3 ± 11 .05 .44 .11 
 
Total - Cf 
(mg/dL) 
 
3.62 ± 0.8  
 
3.75 ± 0.7  
 
3.42 ± 0.6  
 
3.57 ± 0.8 
 
3.35 ± 0.7 
 
3.46 ± 0.5 
 
.09 
 
.34 
 
.97 
HDL - Cf 
(mg/dL) 
1.38 ± 0.2  1.39 ± 0.3  1.37 ± 0.5  1.38 ± 0.4 1.25 ± 0.3 1.31 ± 0.3 .47 .47 .69 
LDL- Cf 
(mg/dL) 
1.82 ± 0.7 1.89 ± 0.6 1.57 ± 0.5 1.68 ± 0.6 1.67 ± 0.5 1.73 ± 0.3 .16 .23 .95 
Triglycerides 
(mg/dL) 
 0.92 ± 0.4 1.04 ± 0.4 1.11 ± 0.9 1.06 ± 0.5 0.94 ± 0.3 0.94 ± 0.3 .63 .62 .51 
Fasting 
glucose 
5.62 ± 0.5 5.36 ± 0.4 5.96 ± 1.0 5.94 ± 1.1 5.56 ± 0.6 5.54 ± 1.0 .33 .08 .33 
HOMA index 1.72 ± 0.7 1.93 ± 1.1 2.32 ± 1.4 2.81 ± 2.4 2.53 ± 1.5 3.18 ± 2.2 .00 .05 .49 
Data are presented as mean ± SD. d: Systolic blood pressure, e: Diastolic blood pressure, f: Cholesterol, m: Interaction.  
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Figure 8. Changes in HRQoL during the study. 
 
Data are presented as percentage, mean ± SE. HB: Home-based group, CB: Centre-based group, 
CG: Control group. White column: Baseline, Dark gray column: one year follow-up. 
 
A 
B 
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DISCUSSION 
The aim of our study was to compare the longer-term effects of a 12-week HB 
exercise programme with tele-monitoring guidance to a prolonged 12-week CB 
cardiac rehabilitation programme following completion of a phase II cardiac 
rehabilitation in patients with CAD. Overall, we showed that HB cardiac rehabilitation 
is as effective as a prolonged CB cardiac rehabilitation program to maintain physical 
fitness and PA levels. We also found maintenance of physical fitness and PA at one 
year follow-up; in fact, 85% of our patients met the international guidelines of 150 
minutes of moderate PA per week (9).  
Contrary to our hypothesis, we could not demonstrate higher levels of physical 
activity at one year of follow-up, in patients randomized to a HB training program 
with tele-monitoring guidance, therefore we could not document higher levels of 
physical fitness compared to the patients enrolled to the CB cardiac rehabilitation 
program or CG. 
Yet, our results are in line with the findings of the FIT@Home study (24) in which 90 
low-to-moderate cardiac risk patients initiating a phase II cardiac rehabilitation 
program were randomized to three months of either HB training with tele-monitoring 
guidance or CB cardiac rehabilitation. At one year of follow-up, they reported an 
improved exercise capacity in both group, without between-group differences. Our 
study complements their results since our intervention started in phase III cardiac 
rehabilitation showing no differences between HB training with tele-monitoring 
guidance and CB training in the long-term (one year). Our results also confirm those 
published in a recent report by Claes et al (14).  By using meta-analytic techniques, 
they showed no influence on exercise capacity in HB cardiac rehabilitation compared 
to usual care when both were offered after completion of a phase II CB cardiac 
rehabilitation programme.  
The results of these studies would suggest that although exercise-based cardiac 
rehabilitation is often aimed at short-term improvement of exercise capacity, it might 
also prepare the patients for independent lifestyle changes that favour the long-term 
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maintenance of the benefits obtained at completion of a phase II cardiac 
rehabilitation programme.  
Frederix et al., published the Telerehab III trial (25, 26), a randomized controlled trial 
(n=140) comparing the efficacy and cost-efficiency of a 24-week tele-rehabilitation 
programme in addition to conventional cardiac rehabilitation versus conventional 
cardiac rehabilitation alone; patients in their intervention were provided with an 
internet-based tele-rehabilitation program in addition to conventional CB cardiac 
rehabilitation. The tele-rehabilitation program was composed of PA tele-monitoring 
in addition to dietary, smoking cessation and activity telecoaching; contrary to our 
intervention, they showed an improvement in exercise capacity in favour of the 
patients receiving tele-rehabilitation. The different outcomes of the studies might be 
explained by the lack of a clear definition for ‘HB cardiac rehabilitation’. As such, the 
contents of HB cardiac rehabilitation interventions that have been investigated varied 
widely and ranged from the use of manuals for a healthier lifestyle to personalized 
exercise prescriptions (14). One such example is the study published by Park et al 
(27), who described a positive adherence study using an intervention of daily text 
messages in combination with a supporting website. The majority of participants 
(85%) in this study reported reading their text messages while the median number 
of visits to the website was only three visits in a six month period, thus they 
suggested that tele-monitoring interventions such as text messaging may have a 
higher likelihood of patient participation and adherence than internet-based 
programs (27). Complementary to the above, Coorey et al hypothesized that 
integrating gamification principles into tele-monitoring technologies may increase 
motivation for sustaining essential, but repetitive, routine lifestyle tasks over the 
longer-term (28). 
During the past years, cardiac tele-rehabilitation was introduced as an adjunct or 
alternative to conventional cardiac rehabilitation to increase uptake rates, enable 
more prolonged care, and improve long-term success (25). Adherence to PA in both 
lifestyle choices and rehabilitation programmes remains to be low. Although we 
observed a small decrease in the proportion of patients meeting the international 
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guidelines for PA, still 85% of patients was doing more than 150 minutes of moderate 
PA one year following completion of the phase II cardiac rehabilitation program, 
which is much more than the 39 to 46% reported in earlier studies (29). We speculate 
that possibly patients underwent a real lifestyle change due to acquired self-
motivation during the cardiac rehabilitation, though behavioural modifications were 
not measured in our study (19).  However, we cannot rule out the impact of a 
selection bias whereby we potentially have recruited the more motivated patients. 
Furthermore, the awareness of follow-up testing could have motivated patients to 
maintain their PA level (30).  
Cowie et al (31), randomized 60 patients with heart failure to home training, hospital 
training or control.  There were no significant differences in mean upright duration, 
steps/day, or walking pattern at long-term assessment. They attributed this lack of 
improvement to the nature of the intervention, which was based on PA alone without 
behavioral counselling as is also the case in our study. Reid et al (32), found a 
significant decrease in habitual PA during long-term follow-up after hospital 
discharge in patients with CAD. In the same line, Hansen et al (8), found that only 
27% of patients participating in cardiac rehabilitation adhered to the minimal PA level 
required to obtain significant health benefits 18 months after completion of a CB 
cardiac rehabilitation program. In the present TRiCH study, at completion of the 
phase II cardiac rehabilitation program, the Sensewear® Mini Armband data showed 
that 85% of our patients did achieve the PA levels recommended for chronic non-
communicable conditions. Furthermore, the PA levels were regular and maintained 
in the long term for all groups. This finding is clinically important since the long-term 
success of cardiac rehabilitation rests in part on the patient’s ability to maintain 
healthy behaviours, including participation in regular PA. Giannuzzi et al (32), 
indicated that continued patient interaction and monitoring, as well as continuation 
of a lifestyle intervention (phase III rehabilitation), is required to obtain long-term 
clinical benefits. However, we considered that prolonging the supervised exercise 
intervention for HB or CB groups in our study would not have resulted in differences 
between groups. 
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Although numerous studies have illustrated the effects of tele-monitoring 
interventions on the incidence of CVD, controversy still remains; a meta-analysis of 
Neubeck et al, has shown significantly favourable changes in total cholesterol, its 
lipoprotein fractions, and smoking habits with telehealth participation compared to 
usual care at medium to long-term follow-up (34). However Gu et al (35), noted that 
several telehealth interventions trials reported non-significant reduction of CVD risk 
factors in patients with prior CAD. Reasons for these different findings could be due 
to different sample sizes, different follow-up duration, and most of all, different design 
of studies centred on cardiovascular risk factors as primary end point which cannot 
detect differences between tele-monitoring and usual care in CVD. We considered 
that the patients included in our TRiCH study were at low risk over the first year after 
enrolment thus the likelihood of detecting a beneficial effect was small. Furthermore, 
the incremental benefit of secondary prevention programs over usual care may be 
very small if the medical management of the patients is probably close to optimal 
(36). 
In relation to HRQoL, Frederix et al (26) evaluated the generic health status through 
the 5Q-5D questionnaire at baseline and at 24 weeks of follow-up.  They described 
an improvement of QoL in their intervention group derived as result of a reduced 
cardiovascular rehospitalization rate while a deterioration in the control group was 
observed during the study period. Kraal et al (24), on the other hand found that 
HRQoL improved on the social and physical subscales at discharge and follow-up in 
HB and CB groups of their FIT@home study. We were unable to detect changes in 
HRQoL for either group after one year of follow-up, however, it remained stable 
during the time of the study, which is important as HRQoL seems to have a bi-
directional relationship with increased PA (19).  
Although the presence of CAD can have a profound impact on physical function, little 
data are available examining the value of HG strength, quadriceps strength and SRT 
in CAD patients after a tele-monitoring intervention in the long term. However, a 
reduction of 15% to 20% in strength has been reported in every decade after 50 
years of age, leading to deleterious effects on the performance of basic activities of 
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daily living (37). Seco et al, described that 26% of adults over the age of 70 could 
not easily climb stairs, 31% had problems carrying a bag weighting 35 kg and 36% 
had walking difficulties. They also described a significant improvement of HG 
strength in 180 independent older adults who completed a simple nine month training 
program (consisting of two sessions per week lasting 55 minutes per session 
including mobility, strength, balance, coordination and walking exercises) and three 
month detraining follow-up. Although no strength differences between the 
interventions were found in our study, there was a significant improvement in 
muscular strength during the follow-up that was not accompanied by improvement 
in muscular strength. We considered the long-term maintenance of HG and 
quadriceps strength in all participants of our groups as a positive result since in older 
individuals, increased muscular strength and endurance tend to reduce disability and 
to improve functional independence and HRQoL, regardless of whether they have 
cardiovascular disease (38). Further research regarding muscle strength and tele-
rehabilitation interventions are needed in order to confirm our results. 
Strengths and limitations 
The present TRiCH study has several strengths. First, we were able to obtained 
objective measures of PA using an accelerometer while previous studies of internet-
based interventions have relied solely on self-reported PA data (39). Second, many 
patients expressed their preference for CB training and were subsequently 
disappointed when allocated to the HB or CG group. However, the randomization 
allowed us to have a proper representation of the cardiac rehabilitation population in 
all groups and their behaviour in the long-term. Third, as described by Claes et al 
(14), although long-term adaptations are the ultimate goal of cardiac rehabilitation, 
the number of that evaluated the longer-term effects of cardiac rehabilitation 
interventions are disappointingly low. Thus the TRiCH study with a follow-up period 
of one year is one of the few studies that allowed a reasonable time frame to assess 
long-term effects of a tele-monitoring program during phase III of cardiac 
rehabilitation.  
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A limitation in this study is the lack of blinding of test personnel. However, as the 
main outcome measure was exercise capacity, the effort of the participants can be 
compared through the respiratory exchange ratio (RER) and the Borg scale (40). 
The study, as do most of randomized controlled trials, had missing outcome data 
due mainly to technical problems or missing numbers in specific tests but these were 
missing completely at random. Cardiac rehabilitation includes important core 
components such as nutritional counselling, risk factor management and 
psychosocial management; but PA training comprises 30-50% (up to >70%) of all 
cardiac rehabilitation activities. Therefore, in this study PA tele-monitoring rather 
than tele-rehabilitation was assessed (41).  
CONCLUSION 
The results of this TRiCH study show that HB cardiac rehabilitation and usual care 
or prolonged CB cardiac rehabilitation are of similar value for maintaining exercise 
capacity, PA anthropometric measures, muscle strength and HRQoL in the long term 
in CAD patients who participated in phase II cardiac rehabilitation. 
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ABSTRACT 
Introduction: Recently, the consumer marketplace has been flooded with an array of 
physical activity monitors. However, little research exists about the reliability and 
validity of these devices. Hence, the purpose of this study was to evaluate the 
reliability and validity of three consumer-based physical activity trackers (Fitbit 
Charge HR, MIO fuse and Sensewear Armband Mini) and one research monitor 
(Actiheart) for estimating energy expenditure (EE) and step count in a phase III 
cardiac rehabilitation (CR) population. 
Methods: Fifteen patients with cardiovascular disease (CVD) in phase III of CR (n=2 
females) aged 56 to 72 years (mean 65.4 ± 6.6) and BMI 26.8 ± 4.8kg/m2 completed 
two sessions of 44-minutes of standardized structured activity within a period of 14 
days. Each session consisted of 10 minutes of rest followed by walking on a treadmill 
at 2.5km/h (slow walk), 4km/h (moderate walk) and 5km/h with 5% incline (brisk 
walk) for 8 minutes each, interspersed with set times for rest. The participants wore 
a MIO Fuse device on their right wrist, Fitbit Charge HR on their left wrist, an 
Actiheart monitor on their chest, a SenseWear armband on the upper left arm and a 
gas analysis system (CPX Ultima; MedGraphics) as criterion for EE. Steps were 
registered through video-recording. Values for EE and steps were obtained for the 
entire protocol as well as per each bout. Reliability was assessed by Intraclass 
Correlation Coefficients (ICC). Validity was determined by ICC, Bland-Altman plots 
and Pearson correlation coefficients.  
Results. For reliability, the ICCs for total EE varied between 0.80 (MIO Fuse) and 
0.95 (SenseWear) with Actiheart having the highest reliability in every stage of the 
session (ICC>0.75) and Fitbit Charge HR the lowest. The ICCs for total number of 
steps varied between 0.38 (MIO Fuse) and 0.91 (SenseWear). As for validity, 
SenseWear, Fitbit Charge HR and MIO Fuse overestimate the EE (0.55%, 11.2% 
and 51.1% respectively) while Actiheart underestimated EE (-4.6%) during the whole 
test. The devices also underestimated the number of steps for every stage, with 
SenseWear showing the highest percentage error (-2.73% to -51.04%) and Fitbit 
Charge HR the lowest percentage error with -0.57%.  
 Chapter 5 | 107 
 
Conclusion: Overall, the inability to accurately estimate EE was notable across all 
devices. Fitbit Charge HR had the lowest reliability concerning EE. For step count, 
results were slightly better with Fitbit Charge HR and SenseWear showing fair to 
good reliability and Fitbit Charge HR and MIO Fuse showing fair to good validity.  
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Introduction 
Despite major improvements in diagnostics and interventional therapies; 
cardiovascular diseases (CVD) remain a major healthcare and socio-economic 
burden both in western and developing countries (1). In fact, CVD remain the leading 
contributor to global mortality and morbidity (2). Currently, it is publicly recognized 
that the fight against these diseases can only be won if their burden is faced by 
increasing the investment in interventions targeting lifestyle changes and prevention 
(1).  
According to the European Society of Cardiology (ESC), secondary prevention by 
means of cardiac rehabilitation (CR) is a Class I recommendation following a cardiac 
event (3). CR is a multidisciplinary intervention of which exercise training is a core 
component and one of the key aims is to encourage patients to achieve the 
recommended levels of physical activity after termination of the phase II CR program 
(4, 5). During the last two decades, great epidemiologic evidence has supported the 
benefits of regular physical activity (PA), and it is widely accepted that higher levels 
of cardiorespiratory fitness and PA are beneficial for the prevention of CVD and the 
reduction in all-cause mortality (6). The ESC guidelines therefore recommend that 
patients with CVD engage in 30 minutes of moderate intensity physical activity on 
most days of the week (7). However, Hansen et al. have shown that  only 27% of 
patients with coronary artery disease adhere to these guidelines 18 months after the 
event(8).  
To increase uptake and adherence to PA recommendations we need new strategies 
and interventions that focus on supporting patients with cardiac disease to sustain a 
healthy and physically active lifestyle (8). Activity tracking devices have the potential 
to affect PA behavior (9). However, to monitor and evaluate the effectiveness of the 
interventions aiming to increase uptake and adherence to a PA lifestyle among CAD 
patients, an accurate assessment tool is mandatory. Physical activity trackers have 
evolved over time from simple mechanical pedometers, to more complex and 
complete accelerometers. The market currently focuses on user-friendly, nice-
looking and wrist-worn activity trackers that link to cell phones and social media 
 Chapter 5 | 109 
 
applications for personalized monitoring. However, despite the widespread adoption 
and potential applications of these devices, there is relatively little information about 
their accuracy and reliability (5).  
Although a wide number of devices are available, most have been validated in 
young, healthy subjects and their applicability to older populations, where 
movements tend to be slower, medication intake is higher and irregularities in heart 
rate are common, is not well established (10). To our knowledge, little research has 
evaluated the reliability and validity of physical activity devices to assess energy 
expenditure (EE) and step count in a phase III CR population under well-controlled 
laboratory conditions. Since living a physically active lifestyle has a  profound and 
multiple benefits not only in healthy population but in older adults and specially 
populations living with chronic illness like CVD and that there is “strong evidence” 
that physically active older adults have higher levels of functional health, lower risks 
of falling, and improved cognitive health;  the purpose of this study was to evaluate 
the reliability and validity of three consumer-based physical activity trackers (Fitbit 
Charge HR, MIO Fuse and Sensewear Armband Mini) to be used in daily life and a 
research monitor (Actiheart) to evaluate  energy expenditure (EE) and step count in 
a phase III CR population. 
Methods  
Study population 
Fifteen patients with CVD, who participated actively in a phase III CR program, were 
enrolled in this study. Participants were included by convenience sampling if they 
were between 60 and 75 years old, had a stable clinical condition in the last six 
months, underwent a negative maximal exercise test in the last six months and had 
absence of significant ventricular arrhythmia or major orthopedic limitations. 
Participants were informed that the test comprised a 44-minute standardized 
treadmill walking protocol and therefore being comfortable on a treadmill was 
desired. The study protocol was approved by the medical ethical committee of the 
University Hospitals Leuven/KU Leuven and participants signed an informed 
consent form before their enrollment. 
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Instruments 
Criterion measures 
To collect EE data, subjects were outfitted with a gas analysis system (CPX Ultima; 
MedGraphics, Minnesota, USA). The device was calibrated automatically for gas 
concentrations and manually for volume with a 3 liter cylinder prior to each 
measurement. The face-mask, attached to a turbine flow meter, allows for real-time 
collection of breath-by-breath VO2 values. These data were used to calculate EE 
from minute averages of VO2. Step count data were collected through video 
recording. Step count data were independently analyzed by two observers, who 
manually counted the number of steps after the session. 
Consumer activity trackers 
The Fitbit Charge HR (Fitbit Inc., San Francisco, USA) is a heart rate and activity 
tracking wristband built to capture movements and health patterns continuously. It 
features Fitbit’s proprietary PurePulse photoplethysmography (PPG) technology, 
which uses green-light infrared LED lights on the inside of the wristband to measure 
heart rate (HR) by detecting blood volume and capillary-size changes under 
pressure. The Fitbit measures general body movements and calculates basal 
metabolic rate (BMR) from participant characteristics: age, gender, height, and 
weight. Through a web-based interface, the Fitbit calculates total kcal/day based on 
each individual’s BMR and his or her general body movements (Fitbit, 2010). Fitbit 
uses three-dimensional motion-sensing technology and converts this into activity 
information including the intensity (light, moderate, vigorous) and duration of 
activities (12). Approximately, the battery last 5 days without recharging. The MIO 
Fuse (Physical Enterprises Inc., Vancouver, Canada) is a commercially available 
PPG and activity tracking wristband developed in collaboration with Philips. The MIO 
Fuse is equipped with a Philips Optical Heart Rate Monitoring Module (OHRM) PPG 
sensor. It is waterproof and the battery capacity allows to measure R-R intervals of 
HR (13). Furthermore, MIO Fuse also carries a 3-axis accelerometer and provides 
estimations of step counts and EE based on proprietary algorithms. Battery life is 6 
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to 7 days for one hour of heart rate monitoring daily, or 24 hours in case of continuous 
heart rate monitoring. 
The SenseWear Armband Mini (SWAM) (BodyMedia Inc., Pittsburgh, USA) is a 
small, non-invasive device that integrates demographic characteristics including 
gender, age, height and weight, a tri-axial accelerometer and heat-related sensors 
including a heat flux sensor to measure galvanic skin response, skin temperature 
and near-body temperature. Sensewear is expected to collect up to 14 days of 
continuous data (24/7), although the battery life is typically reduced under colder 
conditions (14).  
Research activity monitor  
The Actiheart monitor (CamNtech Ltd., Cambridge, United Kingdom) is a 
commercially available unit, which combines measurements of HR and uni-axial 
acceleration. The device collects both parameters with a high resolution. Depending 
on the selected length of the recording epoch, data can be recorded and stored 
continuously for up to 21 days. The monitor has been developed and validated 
during sedentary activities, low-intensity exercise and in children and adolescents 
(15). 
Procedures 
Subjects visited the laboratory twice within 14 days. During visit one, anthropometric 
measures including age, gender; height and weight were taken with the patient 
barefoot and wearing light sportswear. Standing height was measured to the closest 
0.1cm using a stadiometer and the weight was measured to the nearest 0.1kg using 
a digital scale (SECA). As per manufacturer instructions, the devices were 
individualized for age, gender and anthropometric data to allow EE calculation (16). 
Devices with compatible smartphone software were synchronized via Bluetooth to 
an appropriate smartphone to assist with data collection (ease of visualization) (17). 
The participants wore all four devices during a standardized treadmill walking 
protocol. A walking protocol was chosen given that this is the preferred mode of 
physical activity in this patient population. The MIO Fuse was worn on the right wrist 
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and the Fitbit Charge HR was worn on the left wrist. According to the manufacturer’s 
instructions the Actiheart monitor was placed on the participant’s chest using 
standard ECG electrode patches. The SenseWear armband was worn according to 
the manufacturer’s instructions on the participant’s upper left arm. Next, the 
participants were equipped with the indirect calorimetry system. Participants then 
completed a 44-minute standardized treadmill protocol consisting of a 10 minute 
resting condition followed by three walking bouts at distinct speeds and elevations 
(Table 12). During the second visit, participants were fitted with the same devices 
and the same 44-minute protocol was completed.  
Since these consumer-based activity trackers do not provide direct access to the 
raw data, estimates of EE were obtained directly from the trackers or the associated  
application during the test (16). 
Table 12. Standardized treadmill protocol. 
Time Activity 
5 minutes Sitting on a chair 
5 minutes Standing on the treadmill 
8 minutes Walking at 2.5km/h (Slow walk) 
1 minute Standing on the treadmill 
3 minutes Sitting on a chair 
1 minute Standing on the treadmill 
8 minutes Walking at 4km/h (Moderate walk) 
1 minute Standing on the treadmill 
3 minutes Sitting on a chair 
1 minute Standing on the treadmill 
8 minutes Walking at 5.5km/h and 5% inclination (Brisk Walk) 
 
STATISTICAL ANALYSIS 
All data are expressed as means ± SD, median and range or percentages (for 
categorical variables). Statistical analyses were performed using SPSS v.20. The 
Shapiro-Wilk test was used to assess normality. The complete duration of each bout 
was used for the analysis. For EE and steps, test-retest reliability of the devices was 
assessed by calculating the Intraclass Correlation Coefficient (ICC) (two-way 
random, absolute agreement, 95% confidence interval) for the whole session and 
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for each activity, during both visits. An ICC below 0.4 was considered poor, between 
0.4 and 0.75 fair to good and above 0.75 was excellent reliability (20) .  
The validity analysis for EE and steps was performed on the data of the second 
session, unless unavailable, in which case the data from the first session was used 
(2 participants). The validity of the devices was determined by several statistical 
tests. First, the mean absolute percentage error (M.A.P.E) compared to the criterion 
method was calculated for the total session and for each walking speed with the 
following formula for EE: (Calories from device – calories from the criterion 
method/calories from criterion method)*100 and for steps: (steps from device – steps 
from criterion method/steps from criterion method)*100. Second, in order to examine 
the correlation between the devices and the criterion method, the ICC was calculated 
(absolute agreement, two-way random, 95% confidence interval). Third, to examine 
the level of agreement between the devices and the criterion method, Bland-Altman 
plots were constructed, providing calculations of bias along with their limits of 
agreement.  Furthermore, we calculated the mean absolute difference (M.A.D.) 
between the mean from the criterion method and activity tracker. In addition, 
Pearson correlation coefficients were used to assess the strength of the relationship 
between the physical activity trackers and the criterion method in measuring EE and 
number of steps.  
RESULTS 
Sample characteristics 
Participants comprised 93.8% males (n=13), and a mean age of 65.4 ± 6.6 years old 
(range 56-78 years) (Table 13). All participants were part of a phase III cardiac 
rehabilitation community program (HARPA). Due to technical problems, SenseWear 
information was not available for the first session in two participants and for one 
participant in the second session, while Actiheart information was missing for two 
participants in the first session.  
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Table 13. Basic characteristics of the population. 
Characteristics Mean ± SD 
Age (years) 65.4 ± 6.6 
Gender (%)  
Male 93.8 
Female 6.2 
Height (cm) 175 ± 0.7 
Weight (kg) 83.1 ± 16.1 
BMIb (kg/m2) 26.8 ± 4.8 
                                   b: Body mass index. 
Test re-test reliability  
The ICCs between the first session and the second session for total EE varied 
between 0.80 (MIO Fuse) and 0.95 (SenseWear) as can be seen in Table 14. 
Actiheart showed the highest reliability from all devices in every stage of the session 
(ICC>0.75) and Fitbit Charge HR had the lowest reliability in every stage. Reliability 
for MIO Fuse was excellent for the sit/stand period, moderate walking and brisk 
walking, but was fair to poor for slow walking. As for the SenseWear, the reliability 
was poor during the sit/stand period, fair during slow walking, and excellent for 
moderate and brisk walking.  
The ICCs between the first session and the second session for number of steps were 
established for all devices with the exception of Actiheart as can be seen in Table 
15. The ICC varied between 0.03 (MIO Fuse) and 0.96 (Fitbit Charge HR) over the 
different stages of the protocol. SenseWear showed the highest ICC for the complete 
session, as well as the slow and brisk walking (ICC >0.75). The lowest total 
correlation was observed for the MIO Fuse that showed a poor ICC for every stage 
of the protocol. Fitbit Charge HR showed only fair to good correlation for the whole 
session and the slow walking, but an excellent ICC for brisk walking. 
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Table 14. Summary of the reliability analysis for energy expenditure of Fitbit Charge HR, MIO Fuse, Actiheart, 
SenseWear at first and second visit. 
Activity Oxycon Mobile Fitbit Charge HR MIO Fuse 
Calb 1S 
(SD) 
2S 
(SD) 
ICCd (95%CI) 1S 
(SD) 
2S 
(SD) 
Re ICCd 
(95%CI) 
1S 
(SD) 
2S 
(SD) 
Re ICCd 
(95%CI) 
Total session 156 
(39.7) 
157 
(35) 
0.75 
(0.2-0.9) 
165.8 
(17.7) 
165.9  
(10) 
-0.34 -0.94 
(-0.7-0.2) 
211.1 
(66.9) 
237.4 (88.7) -
0.73
* 
0.80 
(0.44-0.93) 
Sit/Stand Period 14.5 
(3.2) 
14.7 
(3.2) 
0.62 
(-0.1-0.8) 
8.8 
(0.41) 
8.8 
(1.08) 
0.64 0.08 
(-2.1-0.7) 
30.6 
(15.1) 
34.06 
(19.07) 
0.65
* 
0.78 
(0.36-0.92) 
Slow Walkf  26.8 
(7.2) 
27 
(6.8) 
0.73 
(0.1-0.9) 
38.8 
(5.1) 
39.6  
(3) 
0.31 0.43 
(-0.7-0.8) 
36  
(15.4) 
47.5 (25.1) 0.30 0.44 
(-0.44-0.81) 
Moderateg Walk  35.9 
(9.3) 
35.2 
(8.4) 
0.72 
(0.1-0.9) 
53.6 
(13) 
50.1  
(2.4) 
-0.11 -0.24  
(-3-0.59) 
49.8  
(19.5) 
51.1  
(23) 
0.83
* 
0.91 
(0.73-0.97) 
Brisk Walkh  59.6 
(15.8) 
59.6  
(13.7) 
0.84 
(0.5-0.9) 
51.7 
(6.2) 
53.4  
(2.2) 
0.09 0.16  
(-1.64-0.72) 
66  
(16.3) 
74  
(21.8) 
0.83
* 
0.85 
(0.48-0.95) 
Activity Actiheart SenseWear 
Calb 1S 
(SD) 
2S 
(SD) 
Re ICCd (95%CI) 1S 
(SD) 
2S 
(SD) 
Re ICCd (95%CI) 
Total session 146.1  
(46.4) 
150.4  
(67.2) 
0.80* 0.87  
(0.59-0.96) 
162.6  
(32.7) 
157.6  
(35.6) 
          0.91* 0.95 
(0.83-0.98) 
Sit/Stand Period 14.5 
(3.07) 
14.6 
(3.22) 
0.90* 0.96 
(0.89-0.99) 
12 
(1.74) 
12.2 
(2.28) 
0.94* 0.18  
(-0.01-0.59) 
Slow Walkf  28  
(13.2) 
26.4  
(8.8) 
0.81* 0.87  
(0.59-0.96) 
39.5  
(9.2) 
36.6  
(9.6) 
0.57* 0.68  
(-0.02-0.90) 
Moderateg Walk  39.9  
(13.7) 
40.3  
(21.7) 
0.70* 0.77  
(0.25-0.93) 
45.1  
(11.1) 
44.5  
(11.5) 
0.89* 0.94 
(0.79-0.98) 
Brisk Walkh  46.6  
(18.5) 
51.3  
(29.3) 
0.75* 0.80  
(0.35-0.93) 
48  
(9.9) 
47.1  
(9.3) 
0.95* 0.97 
(0.88-0.99) 
b: Calories, e= Pearson’s Correlation, d: Intraclass correlation, (95%CI): 95% Confidence Interval, SD: Standard Deviation, f: 2.5km/h, g: 4km/h, h: 
5.5km/h with 5% incline. *= Correlation is significant at the 0.05 level (two-tailed). 
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Table 15. Summary of the reliability analysis for number of steps with Fitbit Charge HR, MIO Fuse and SenseWear 
at first and second visit. 
Activity Fitbit Charge HR   MIO Fuse  SenseWear 
Steps 1S 
(SD) 
2S 
(SD) 
Re ICCd 
(95%CI) 
1S 
(SD) 
2S 
(SD) 
Re ICCd 
(95%CI) 
1S 
(SD) 
2S 
(SD) 
Re ICCd 
(95%CI) 
Total session 2550.6 
(91.2) 
2593 
(142.1) 
0.54* 0.64 
(0.16-0.87) 
2444.6 
(212.2) 
2518 
(184.4) 
0.24 0.38 
(-0.73-0.79) 
2165 
(238.7) 
2196 
(237.2) 
0.82* 0.91  
(0.68-0.97) 
Slow Walkf  699.4  
(63.7) 
718 
(75.4) 
0.33 0.49 
(-0.48-0.83) 
665.1 
(177) 
745.8 
(97.7) 
0.23 0.30 
(-0.74-0.75) 
417.7 
(189.1) 
394.9 
(232.7) 
0.87* 0.92 
(0.72-0.97) 
Moderate 
Walkg  
874.8  
(48.1) 
889.2 
(56) 
0.15 0.27 
(-1.21-0.75) 
886.9 
(141.6) 
871.7 
(60.9) 
0.02 0.03 
(-2.26-0.68) 
854.5 
(50.1) 
863.1 
(70.4) 
0.44 0.60 
(-0.45-0.88) 
Brisk Walkh  924 
(59.2) 
931 
(61.7) 
0.94* 0.96  
(0.90-0.98) 
893 
(120.4) 
901.8 
(122.8) 
0.09 0.18 
(-1.73-0.73) 
892.8 
(50) 
912 
(61) 
0.82* 0.87 
(0.54-0.96) 
e= Pearson’s Correlation, d: Intraclass correlation, (95%CI): 95% Confidence Interval, SD: Standard Deviation, f: 2.5km/h, g: 4km/h, h: 5.5km/h 
with 5% incline. *= Correlation is significant at the 0.05 level (two-tailed). 
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Validity 
The M.A.P.E for total session EE between the devices and the criterion method 
showed that SenseWear slightly overestimated the EE (0.55%), as well as Fitbit 
Charge HR (11.2%) and a consistently higher overestimation with MIO Fuse 
(51.1%). Actiheart estimates for total EE were consistently lower (-4.6%) compared 
to the criterion method. During the sit/stand condition, an overestimation of EE was 
detected with the MIO Fuse. As for the different walking speeds, an overestimation 
of EE was observed with all devices during slow walking ranging from 0.7% 
(Actiheart) to 86.8% (MIO Fuse) and moderate walking ranging from 13.9% 
(Actiheart) to 50.1% (Fitbit Charge HR). During the brisk walk however, only MIO 
Fuse overestimate EE by 25.7% while Actiheart (-13.7%), Fitbit Charge HR (-3.7%) 
and SenseWear (-20.2%) underestimated the EE. The M.A.P.E for EE is shown in 
Figure 9A. Figure 9B illustrates the M.A.P.E for number of steps for Fitbit Charge 
HR, MIO Fuse and SenseWear compared to the criterion method. On average, the 
devices underestimated the number of steps for every stage, with   SenseWear 
showing the biggest percentage ranging from -2.73% (brisk walk) to -51.04% (slow 
walk). For the whole session, Fitbit Charge HR had the smallest percentage error 
with -0.57%.  
 
 
 
 
 
 
 
 
 
 
 
 
118 | Chapter 5 
 
Figure 9. Mean absolute percentage error for EE and steps between devices 
and criterion methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9A shows the mean absolute percentage error (M.A.P.E) for EE when devices are 
compared to the criterion method during the whole session, sit and stand and different 
walking speeds (slow, moderate and brisk).  9B. M.A.P.E for step count when devices are 
compared to criterion method during the whole session and the different walking speeds. 
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Table 16 illustrates the ICC between the activity trackers and the criterion method 
related to EE. The mean EE measured by the criterion method was 157 ± 35.2 
calories for the whole session, while the mean calories measured by the devices 
ranged from  150 ± 62.7 (Actiheart) to 237.5 ± 88.7 (MIO Fuse). On average, 
correlations were fair to poor for all devices except for Actiheart during sit/stand 
period, where the correlation was excellent. 
The mean number of steps for the whole session was 2579 ± 125.33 according to 
the criterion method and the devices reported values ranging from 2142.93 ± 222.45 
(SenseWear) to 2593.06 ± 142.12 (Fitbit Charge HR). In general, Fitbit Charge HR 
and MIO Fuse showed an excellent correlation with the criterion method. However, 
this was not the case in every stage of the session. Fitbit Charge HR had a poor to 
fair correlation for moderate walking while MIO Fuse showed a poor to fair correlation 
during brisk walking. On the other hand, SenseWear had the worst correlations for 
step counts compared with the criterion method with poor values for total session 
and slow walking, but excellent correlation for moderate and brisk walking. Table 17 
provides detailed information on every stage of the test for each device concerning 
the step count. 
Finally, Figure 10 shows the Bland-Altman plots for EE and Figure 11 shows the 
Bland-Altman plots for number of steps. Graphically, there is a low agreement 
between the devices and the criterion method, demonstrating also that MIO Fuse 
has the greatest variability for estimated EE (-223.41, 62.61,). Fitbit Charge HR 
showed a better level of agreement compared to the criterion methods for both EE 
and step count. 
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Table 16. Validity of physical activity devices for energy expenditure. 
Calories Parameters Calories  
Mean ± SD 
M.A.Db LoA (U)c LoA (L)i Re ICCd (95% CI) 
Total session 
Criterion method 157.06 ± 35.16      
Fitbit 165.93 ± 10.08 -8.86 ± 36.61 62.89 -80.61 -0.00 -0.00 (-2.03,0.66) 
MioFuse 237.46 ± 88.71 -80.40 ± 72.96 62.61 -223.41 0.60 0.39 (-0.28,0.77) 
Actiheart 150 ± 62.69 7.06 ± 55.94 116.70 -102.58 0.46 0.57 (-0.30,0.86) 
Sensewear 154.80 ± 33.25 2.26 ± 32.59 66.14 -61.61 0.54 0.72 (0.13,0.90) 
Sit/Stand 
Criterion method 14.72 ± 3.25      
Fitbit 8.80 ± 1.08 5.92 ± 2.79 0.45 11.38 0.56* 0.15 (-0.14,0.53) 
MioFuse 34.06 ± 19.07 -19.34 ± 17.11 14.20 -52.89 0.65* 0.20 (-0.21,0.63) 
Actiheart 14.68 ± 3.02 0.40 ± 2.68 5.65 -4.85 0.63 0.78 (0.35,0.93) 
Sensewear 12.04 ± 2.17 2.67 ± 2.99 8.54 -3.18 0.39 0.44 (-0.26,0.79) 
Slow walkf 
Criterion method 27.06 ± 6.86      
Fitbit 39.6 ± 3 -12.60 ± 8.16 3.39 -28.59 -0.24 -0.10 (-0.37,0.32) 
MioFuse 36 ± 15.4 -9.19 ± 12.04 14.40 -32.79 0.20 0.57 (-0.13,0.85) 
Actiheart 26.46 ± 8.88 0.60 ± 8.25 16.78 -15.58 0.47 0.64 (-0.10,0.88) 
Sensewear 36.06 ± 9.63 -8.99 ± 10.52 11.63 -29.62 0.22 0.24 (-0.42,0.68) 
Moderate 
walkg 
Criterion method 35.28 ± 8.41      
Fitbit 50.13 ± 9.56 -14.85 + 11.33 7.35 -37.05 0.21 0.16 (-0.26,0.58) 
MioFuse 51.1 ± 23 -15.85 ± 20.21 23.77 -55.47 0.49 0.37 (-0.34,0.76) 
Actiheart 40.37 ± 21.78 -5.09 ± 20.10 34.30 -44.49 0.38 0.41 (-0.72,0.80) 
Sensewear 43.83 ± 11.42 -8.54 ± 9.9 10.85 -27.95 0.53 0.55 (-0.17,0.84) 
Brisk walkh 
Criterion method 59.65 ± 13.72      
Fitbit 53.46 ± 8.83 6.18 ± 17.74 40.95 -28.59 -0.35 -0.86 (-4.42,0.37) 
MioFuse 74 ± 21.8 -14.41 ± 18.84 22.52 -51.34 0.52 0.53 (-0.17,0.83) 
Actiheart 51.3 ± 29.38 8.35 ± 28.74 64.69 -47.99 0.28 0.34 (-0.85,0.77) 
Sensewear 46.81 ± 9.07 12.84 ± 9.16 30.80 -5.11 0.75 0.60 (-0.25,0.88) 
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Table 16 illustrates the correlations between the activity trackers and the criterion method related to EE. b=Mean absolute difference, c: Level of 
agreement upper, i= Level of agreement lower, e= Pearson’s Correlation, d= Intraclass correlation. (95%CI)= 95% Conf idence Interval. f: 2.5km/h, 
g: 4km/h, h: 5.5km/h with 5% incline. *= Correlation is significant at the 0.05 level (two-tailed). 
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Table 17. Validity of physical activity devices for number of steps. 
 Parameters Steps  
Mean ± SD 
M.A.Db LoA (U)c LoA (L)i Re ICCd (95% CI) 
Total 
session 
Video 2579 ± 125.33      
Fitbit 2593.06 ± 142.12 -14.06 ± 91.47 165.22 -193.35 0.77* 0.87 (0.62,0.95) 
MioFuse 2518.80 ± 184.48 60.20 ± 101.68 259.50 -139.10 0.85* 0.85 (0.52,0.95) 
Sensewear 2142.93 ± 222.45 436.06 ± 198.9 825.91 46.20 0.46 0.18 (-0.14,0.57) 
Slow walkf 
Video 745.8 ± 65.72      
Fitbit 718.06 ± 75.49 27.73 ± 24.80 76.34 -20.87 0.94* 0.93 (0.38,0.98) 
MioFuse 745.86 ± 97.74 -0.06 ± 60.59 118.69 -118.83 0.79* 0.85 (0.56,0.95) 
Sensewear 370.46 ± 213.59 375.33 ± 191.81 751.28 -0.61 0.46 0.13 (-0.15,0.50) 
Moderate 
walkg 
Video 894.46 ± 45.38      
Fitbit 889.26 ± 56.05 5.20 ± 50.26 103.71 -93.31 0.52* 0.69 (0.05,0.89) 
MioFuse 871.73 ± 60.99 22.73 ± 29.68 80.92 -35.45 0.88* 0.88 (0.48,0.96) 
Sensewear 860.66 ± 64.54 33.80 ± 38.61 109.49 -41.89 0.80 0.78 (0.14,0.93) 
Brisk walkh 
Video 938.73 ± 56.52      
Fitbit 931.0 ± 61.75 7.73 ± 15.70 38.52 -23.05 0.96* 0.97 (0.93,0.99) 
MioFuse 901.86 ± 122.87 36.86 ± 101.67 236.14 -162.40 0.57* 0.59 (-0.13,0.85) 
Sensewear 912.46 ± 59.04 26.26 ± 41.97 108.54 -56.00 0.73* 0.80 (0.38,0.93) 
Table 17 illustrates the correlations between the activity trackers and the criterion method related to number of steps. b=Mean absolute difference, 
c: Level of agreement upper, i= Level of agreement lower, e= Pearson’s Correlation, d= Intraclass correlation. (95%CI)= 95% Confidence Interval. f: 
2.5km/h, g: 4km/h, h: 5.5km/h with 5% incline. *= Correlation is significant at the 0.05 level (two-tailed).
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Figure 10. Bland-Altman plots for energy expenditure 
A  B  
C  D  
Difference of total calories measured between the device and criterion method 10A: Fitbit Charge 
HR, 10B: MIO Fuse, 10C: Actiheart, 10D: SenseWear. The solid line corresponds to the mean 
difference, while the dashed lines correspond to the limits of agreement. 
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Figure 11. Bland-Altman plot for Fitbit Charge HR, MIO Fuse and SenseWear 
A  
B  
C  
Difference of total steps between the device and the criterion method. 11A Fitbit Charge HR, 11B: 
MIO Fuse and 11C: SenseWear. The solid line corresponds to the mean difference, while the dashed 
lines correspond to the limits of agreement. 
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DISCUSSION 
This study highlighted the difficulties around the accurate estimation of EE by most 
PA devices in an older cardiac patient population during a common daily activity like 
walking. Yet, with the exception of the Fitbit Charge HR, all devices did show an 
excellent reliability for EE but with a low level of validity. Reliability for step count was 
fair to good for SenseWear and Fitbit Charge HR; MIO Fuse and Fitbit Charge HR 
showed fair to good validity for number of steps.  
Reliability and validity of EE 
Physical activity is a major component in a CR program and is integral to recovery 
from coronary heart disease (CHD) (5). It is also a multi-dimensional complex human 
behavior that can be described  by the following parameters: i.e. type, pattern, 
duration and intensity of physical tasks and can be quantified by determining EE 
(21). In order to evaluate the effects of physical activities such as walking or jogging 
on the progression of the existing chronic disease,  an accurate measurement of the 
volume of physical activity is needed (22). New physical activity trackers regularly 
enter the market, with advances in technology contributing to dramatic 
improvements, like inbuilt accelerometers for smartphone-based devices and 
wearable physical activity devices (5). From the four devices we investigated, Fitbit 
Charge HR showed the worst reliability and validity for determination of EE. Contrary 
to our results, Noah et al (23) found the Fitbit and Fitbit Ultra as reliable and valid 
devices for determining EE while walking and jogging without an incline in twenty-
three subjects that participated in 6-min bouts of treadmill walking, jogging and stair 
stepping. Our results might be explained by the placement of the devices, while Fitbit 
and Fitbit Ultra are placed on the waistline, Fitbit Charge HR is a wrist worn 
accelerometer. The placement of the devices is important as recent research 
indicates that wrist worn accelerometers might not be as accurate as waist worn 
devices (24). The SenseWear and Actiheart had an excellent reliability (except for 
the Sit and Stand period for SenseWear) and a fair to good validity during the whole 
test and most of the phases except for brisk walk (Actiheart) and slow walk 
(SenseWear) in this cardiac population. These results are in line with previous 
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studies involving the Actiheart, which was the first commercially available device that 
combined a heart rate monitor and accelerometer into a single unit (25). In general, 
the Actiheart has been shown to provide accurate EE estimates of low-to-moderate 
intensity activities performed in a laboratory setting as well as during treadmill 
walking and running in healthy adults (25, 26). The poor correlation during brisk walk 
might be explained by the poor relative performance of the accelerometer 
component of the Actiheart. Spierer et al. estimated EE from the device during low 
intensity activities, walking and jogging describing mixed results depending on which 
activities were examined. They found that the Actiheart performs better during 
activities in which EE is not directly related to pelvic acceleration (card playing, 
weight lifting, and sweeping). They hypothesized that the location of the 
accelerometer component on the chest may be problematic due to the significant 
damping of acceleration forces which occurs in the torso during walking, compared 
to acceleration that occurs at the pelvis (27).   
Several studies have been published on the validity of different models of 
SenseWear armband (28, 29). Early research has shown that the SenseWear Pro 2 
armband can accurately estimate resting EE in healthy young (30) and obese 
subjects  (31). The validity of SenseWear has also being tested with clinical 
populations including individuals with chronic obstructive pulmonary disease 
(COPD), cystic fibrosis, and arthritis (32-34). Van Remoortel et al. found that for 
estimating EE, SenseWear is a valid monitor during standardized physical activities 
in COPD patients (34). Cole et al (35) however, concluded that the accuracy of the 
SenseWear (version 2.2) appears to be exercise modality dependent in patients with 
heart disease when using software developed for general population. Fruin and 
Rankin (36) found that the SenseWear was valid and reliable for measuring resting 
EE, but it overestimated the EE of treadmill walking without inclination and 
underestimated the EE of treadmill walking up an incline. In our study however, the 
validity of SenseWear was fair for slow walk with a poor reliability for sit and stand. 
A possible reason for these results might reside in the software version used to 
analyze the data (Version 7.0). In a doubly labelled water validation study, the 
SenseWear Pro 2 with software version 5.1, but not version 6.1, was found to be 
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valid in overweight and obese children (37). The SenseWear accuracy seems to be 
improving over time, but researchers should follow the results of validation studies 
and be aware of which software version they are using (37).  
As for MIO Fuse, only a few studies have been published previously (38, 39)  
validating devices from the same company (MIO Global) for heart rate monitoring, 
but information related to EE is scarce. It is difficult to speculate what contributed to 
errors of this device. It is assumed that each device has a specific algorithm for the 
determination of EE, however this information is not disclosed by the companies 
(17). 
Reliability and validity on number of steps 
 Step counts are a simple way to quantify the amount of physical activity and are 
being used extensively in health promotion campaigns by governments and 
international organizations (22). 
According to Tudor-Locke et al. (40) activity monitors should not exceed a 1% error 
deviation (M.A.P.E) from the gold standard during walking on a treadmill at a speed 
of 3mph (4.8 km/h) in order to be considered accurate. Only Fitbit Charge HR fitted 
this criterion. SenseWear had an error deviation slightly higher than the 1% threshold 
(-2.7%) while MIO Fuse exhibited the greatest deviation errors during the brisk walk 
(-4%). Similar to our results, Takacs et al.(22) found a percent relative error of Fitbit 
One less than 1.3% for number of steps in thirty volunteers during five pre-
determined speeds on a treadmill, while Manns et al.(41), reported a constant 
underestimation of steps by the SenseWear in persons with stroke. 
In our study, Fitbit Charge HR and MIO Fuse demonstrated a good to excellent 
agreement with the gold standard for the whole session and almost every separate 
stage (Fitbit Charge HR was fair to good during moderate walking and MIO Fuse 
had the same result for brisk walking). SenseWear showed the lowest ICC for the 
whole session. Takacs et al (22) found correlations between 0.97 and 1.0 for five 
different speeds on a treadmill for the Fitbit One. Although in our study, the 
correlation for the Fitbit Charge HR was somewhat lower (ICC 0.87), it is still 
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considered excellent. As for SenseWear, Manns et al. (41) found a poor agreement 
between the device and their criterion method (ICC = 0.352) which can be compared 
to the poor agreement in our study (ICC = 0.18) for the whole session, however, in 
our study results were excellent for moderate walking (ICC = 0.88) and brisk walking 
(ICC = 0.80). 
The majority of activities in daily life are intermittent in nature, intensity and duration. 
Thus, research on activity devices in laboratory settings (such as treadmill walking) 
may not be generalizable to overall activities in free-living conditions (42). To date, 
only one study measured the accuracy of MioFuse and Fitbit Charge HR in 
laboratory and free living conditions. Their population consisted of forty healthy 
young adults (21.6 ± 2 years) that performed four five-minute stages at different 
speeds on a treadmill and wore the devices during walking hours of the ensuing day 
to obtain free-living data (42). The authors concluded that MIO Fuse substantially 
underestimated steps compared to Fitbit in free-living observation probably due to 
its difficulty in detecting sporadic movements. Further research is needed under free-
living conditions to support these findings. 
It seems that the investigated devices should not be recommended for tracking of 
exercise progress in a phase III cardiac rehabilitation population, even though they 
could be of use as a motivational tool. 
Strength and limitations 
Our results are based on laboratory settings involving only treadmill walking at 
different speeds and inclination. It is not known how well the results apply to free-
living conditions or other physical activities since under free-living conditions there 
could be an increased variety of intensities, directions and waking speeds (43). 
However, validating physical activity tracking devices under free-living conditions 
presents the inability to us a gold standard criterion method for EE or number of 
steps. 
The information provided by this study however, may be useful to researchers and 
medical personnel attempting to make practical decisions regarding the selection of 
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devices to measure physical activity in cardiac patients. The complete walking bouts 
were used for the analysis of each device including the first and last minute of every 
stage, although a difference in acceleration could be present during these moments, 
their influence on our results cannot be establish since the filtering and processing 
of acceleration signals for the trackers is not publically available. 
CONCLUSSION  
This study documented a noteworthy inability of the Fitbit Charge HR, MIO Fuse, 
SenseWear Armband Mini and Actiheart to accurately estimate EE. It is difficult to 
speculate what contributed to errors of this magnitude for EE (17).  However it is 
assumed that the devices have errors related to shortcomings of the used algorithms 
for the determination of EE and unfortunately, this information is not disclosed by the 
manufacturing companies. However, validity and reliability were higher for step 
counts. Fitbit Charge HR had an excellent validity for number of steps with fair to 
good test re-tests reliability, MIO Fuse showed good validity, but with a poor 
reliability.  
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Cardiac rehabilitation has evolved considerably since the 1930s and is now viewed 
as a comprehensive multidisciplinary approach to complex medical conditions 
requiring behavioural, physical, emotional, and social care management in the 
secondary prevention of CAD (1). Exercise-based cardiac rehabilitation has been 
shown to reduce mortality, prevent hospital readmission and improve quality of life 
(2). Nonetheless, despite the clinical effectiveness of centre-based cardiac 
rehabilitation, the long-term clinical effectiveness of this intervention is often poor, 
due to the lack of attendance at rehabilitation sessions and non-adherence in the 
longer-term to lifestyle recommendations (3). Recent advances in information and 
communication technologies, such as smartphones and the internet, have shown 
potential to address some of the barriers through home-based cardiac rehabilitation 
programmes (4).  
Therefore, the main scope of this doctoral project was to compare the short and long-
term effects of a 12 week home-based cardiac rehabilitation program with tele-
monitoring guidance in CAD patients.  This final chapter summarizes and discusses 
the main findings of the TRiCH study complemented with findings on the validity and 
reliability research on PA trackers to create an overall understanding of the effects 
of tele-monitoring in CAD patients. The strengths and limitations of this doctoral 
research will also be discussed, followed by future research recommendations 
closing with the general conclusions of our research. 
Summary of main findings 
Chapter 2: In this chapter, we described the rationale, design and methods of the 
Tele-Rehabilitation in Coronary Heart disease study (TRiCH). The main objective of 
the TRiCH study was to compare the long-term effects of a 3-month HB cardiac 
rehabilitation program with tele-monitoring guidance in CAD patients (phase III) with 
a supervised CB cardiac rehabilitation program and a CG. We used exercise 
capacity measured as peak oxygen uptake (VO2P) at 12 months as the main 
outcome and hypothesized that patients randomized to a HB training cardiac 
rehabilitation program with tele-monitoring guidance will demonstrate higher levels 
of PA at one-year of follow-up, resulting in higher levels of exercise capacity, 
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compared to the other two groups. Secondary outcomes included PA, muscle 
function, HRQoL and traditional cardiovascular risk factors.  
The second objective was to determine the differential effect of HB cardiac 
rehabilitation versus CB cardiac rehabilitation on exercise capacity in the short-term; 
hypothesizing that in CAD patients on phase III of cardiac rehabilitation, HB cardiac 
rehabilitation will have a larger effect compared to the CG, but similar to CB cardiac 
rehabilitation.    
The study was planned initially as a randomized controlled trial including 105 CAD 
patients to one of three groups: HB, CB or usual-care group (CG). The enrolment 
started in February 2014 and was expected to finish in November 2015. However, 
recruitment of participants went slower than anticipated due to logistical issues in the 
hospital. As a result, the recruitment ended in August 2016 and we could only recruit 
90 patients. 
Chapter 3: Cardiac rehabilitation is an essential part of contemporary coronary heart 
disease management. Yet, many patients exiting a CB cardiac rehabilitation 
program have difficulty retaining its benefits. Thus, we aimed to evaluate the second 
objective of the TRiCH study (Chapter 2) by establish the short-term effect of a HB 
cardiac rehabilitation program with tele-monitoring guidance on exercise capacity 
and other secondary outcomes in CAD patients in phase III of cardiac rehabilitation. 
The result of this study showed that a 3-month HB training intervention with tele-
monitoring guidance is as effective as a prolonged CB cardiac rehabilitation. The 
changes obtained with an average training intensity below the recommended 
thresholds in our population led us to believe, as described previously by Swain and 
Franklin (1), that in healthy individuals, with a mean baseline VO2max <40 mL∙kg-
1∙min-1, intensities above 40% of heart rate reserve can still bring improvements in 
exercise capacity. As for secondary outcomes, a small but significant increase in 
sedentary time was found in the CB group. We considered this behaviour as a 
compensatory effect for exercise (2), meaning that the simple fact of enrolling in a 
supervised exercise program might reduce PA levels throughout the rest of the day. 
Based on these results it was concluded that a HB cardiac rehabilitation with tele-
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monitoring guidance can be an effective alternative to CB cardiac rehabilitation for 
further maintain exercise capacity following phase II of cardiac rehabilitation and 
although short-term changes are of interest, it was important to establish whether 
the benefits were maintained in the long-term. 
Chapter 4: HB interventions have been shown to enhance a patient’s self-efficacy 
and might facilitate the lifelong uptake of a physically active lifestyle. However, data 
on the long-term effectiveness of HB exercise training on PA and exercise capacity 
are scarce. Hence, following the main purpose of the TRiCH study (Chapter 2), we 
compared the long-term effects of the implementation of a short HB phase III 
exercise program with tele-monitoring guidance to a prolonged CB cardiac 
rehabilitation program in CAD patients. Contrary to our hypothesis, we could not 
demonstrate higher levels of PA at one year of follow-up in patients randomized to 
a HB training program, however, we showed that HB cardiac rehabilitation was as 
effective as a prolonged CB cardiac rehabilitation program in the maintenance of PA 
and exercise capacity. Overall, 85% of patients in our study maintain their PA levels 
independently of the group of randomization which led us to believe that they were 
prepared for independent lifestyle changes, favouring the maintenance of long-term 
benefits after the completion of a phase II cardiac rehabilitation program.  
Chapter 5: The ESC guidelines recommend that patients with CAD engage in 30 
minutes of moderate intensity PA on most days of the week (3). Since activity 
tracking devices have the potential to affect PA behaviour and make a direct and 
real-time impact on self-management of PA (4), we evaluated the validity and 
reliability of Fitbit Charge HR, MIO fuse, SenseWear Armband Mini and Actiheart for 
estimating energy expenditure and step count in CAD patients on phase III of cardiac 
rehabilitation. Our results showed that overall, the inability to accurately estimate 
energy expenditure was notable across all devices. By consequence, we did not 
recommend the studied devices for tracking the energy expenditure in a population 
of CAD patients on phase III of cardiac rehabilitation. 
Appendices: Resveratrol is a polyphenol with anti-oxidant, anti-inflammatory, and 
cardio protective properties, and has been shown to reduce oxidative damage in the 
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aorta of aged rats (5). Since patients with CAD commonly present endothelial 
dysfunction, we intended to investigate whether acute supplementation with high 
doses of Resveratrol would improve flow-mediated dilation and oxygen kinetics in 
ten CAD patients on phase III cardiac rehabilitation. We found that the 
supplementation improve flow-mediated dilation in patients after CABG. However, 
our study should be interpreted within the context of its limitations that include the 
limited number of patients and the used of indirect measures.  
Effectiveness of a HB cardiac rehabilitation program with tele-monitoring guidance 
in improving exercise capacity in the short-term and long-term 
In Chapter 3 we demonstrated that adding a HB exercise program in the early stage 
of phase III cardiac rehabilitation results in a further improvement of exercise 
capacity and is equally effective as a prolonged CB cardiac rehabilitation in patients 
with CAD.  
In the TRiCH study, the home-based intervention consisted of a 12-week program 
with weekly follow-up on exercise compliance and adherence. A commercially 
available heart rate monitor (Garmin Forerunner 210) was provided to patients 
randomized to the HB group. As described in Chapters 2 and 3, the patients trained 
the first three sessions under the supervision of the researchers for acquaintance 
with the tele-monitoring system (use of the heart rate monitor) and were instructed 
to use the device during the training sessions. Additionally, patients were instructed 
on how to upload the information to the Garmin web application 
(http://connect.garmin.com). The application provided graphical information on the 
type of activity, duration of the activity and heart rate during each of the training 
sessions (minimum, maximal and average) as shown in Figure 12. The application 
was accessed by both patients and the researchers. Patients were advised to follow 
the current physical activity recommendations as formulated by the European 
Society of Cardiology: i.e. to exercise for at least 150 minutes a week (at least 3 
times/week, preferably 6 to 7 days/week) at an individually determined target heart 
rate corresponding to moderate intensity (70-80% HRR) (6). The time patients spent 
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within the recommended heart rate zone was assessed by means of the garmin 
training centre program.  
 
 
Figure 12. Platform garmin connect. Patients were encourage to upload their information after each 
training or once a week according to their preferences. 
 
Patients were asked about their preferred contact method: e-mail (40% of 
participants) or phone call (60% for weekly feedback. The purpose of the feedback 
was twofold. First, to discuss adherence and compliance with the exercise 
prescription in the home environment and to evaluate motivational issues and 
incidence of injuries or adverse effects related to exercise. Patients opting for e-mail 
as their preferred method of feedback were given two days to reply a message after 
which a reminder email was sent. Figure 13 shows an example of one of the 
messages. We used short texts to make it fast and clear for participants, however 
its content was adapted according to patient’s needs. In cases of questions related 
to training or technical problems with the device, patients were stimulated to contact 
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the researchers for further help. After 12 weeks, the weekly contacts terminated but 
patients were advised to continue their training with or without the heart rate monitor. 
 
Figure 13. Patients were contacted according to their preference (phone call or email), the intensity, 
duration and frequency of the training was discuss weekly. 
 
In line with our results, systematic reviews have shown the benefits of telehealth 
programmes when compared to usual care (7-9). Huang et al. reviewed the 
effectiveness of mainly phone-based telehealth interventions versus CB care in 1546 
low to moderate risk CAD patients (8). They found no difference between the former 
and latter care delivery strategy for exercise capacity, cardiovascular risk factors, 
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mortality, quality of life (HRQoL) and psychosocial state. Hwang et al. compared 
remote rehabilitation with on-site care delivery in 908 CAD, chronic heart failure 
and/or respiratory disease patients (10). Tele-rehabilitation was shown to be as 
effective as CB cardiac rehabilitation in terms of exercise capacity and quality of life. 
Currently, the most common communication technology is smartphone, followed by 
email, and text messages (11).  
When it comes to long-term, we found no further improvement in exercise capacity 
as discussed in Chapter 4. Contrary to our results, Smith et al (12) followed during 
12 months a total of one hundred and ninety-eight patients after discharge from a 
randomized controlled trial of 6 months of monitor “home” versus supervised 
“hospital” cardiac rehabilitation after CABG. They found a declined in VO2P in the 
“hospital” but not in the “home” group (P = 0.002). They suggested that if the exercise 
component of cardiac rehabilitation was initiated in the home environment and 
monitored for 6 months, the improvements will be maintained for at least an 
additional 12 months after the cessation of cardiac rehabilitation. Their study 
however was developed during phase II cardiac rehabilitation and patients only 
experienced “home” or “hospital” program. On the other hand, in the Telerehab III 
trial, Frederix et al (13, 14) observed a difference in favour of the patients receiving 
tele-rehabilitation. We considered that the changes could be attributed to the longer 
duration of the intervention in the Telerehab III study (24-weeks) compared to the 
TRiCH study (12-weeks). Another important aspect not fully disclosed in Chapter 4 
is related to the population included in the TRiCH study. Reasons for no-enrolment 
in cardiac rehabilitation usually include dislike of exercise, low exercise capacity or 
the perception that exercise is tiring or painful (15). Even though our population was 
randomized, we actively recruited patients who were already enrolled in phase II of 
cardiac rehabilitation potentially leading to a biased sample population; we assumed 
that our participants did like being physically active which is supported by the 
maintenance of their PA and exercise capacity after a year of inclusion. Traditionally, 
older age, female sex, a racial-ethnic minority group, low socioeconomic status, 
work-related factors, limited or lack of health insurance, multiple comorbidities, and 
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health care system factors have been associated with low referrals or enrolment rate 
(16, 17).  
Thus, further research is needed to establish if a longer intervention with tele-
monitoring guidance or a hybrid intervention (home-based additional to centre-
based) for a specific CAD population could have a greater impact in the long-term.   
Notwithstanding what has just been said, our results nicely complemented the 
previous publications on tele-monitoring and HB training showing that this novel care 
delivery strategy has the potential to become an alternative to CB cardiac 
rehabilitation. That is,  HB programmes could be a beneficial option for patients who 
do not like or are not able to take part in a CB cardiac rehabilitation since it can be 
delivered in non-clinical settings, such as the home or community and consequently 
increase uptake of cardiac rehabilitation overall. In line with other studies we also 
illustrated that patients are able to independently execute a training programme in 
their home environment for 12-weeks when they receive weekly feedback (18). 
Effectivenessof a HB cardiac rehabilitation program with tele-monitoring guidance 
on PA, anthropometric measures, muscle strength, traditional cardiovascular risk 
factors and HRQoL in the short-term and long-term. 
Overall, our intervention did not affect the PA levels of the participants and we were 
unable to increase the PA in our population. In the short-term an increased in 
sedentary behaviour was seen on the CB group as described in Chapter 3, 
nevertheless in Chapter 4 we found no differences between groups in PA. Contrary 
to our results, Van den Berg et al in a systematic review (19), reported that online 
interventions are effective in improving PA levels. However, objective measures 
such as activity monitors or pedometers were rarely used. Thus, our study add to 
the limitations of previous publications by exploring the results with a defined control 
group as well as with an objective PA outcome measure. A recent systematic review 
by Veen et al (20) included 19 RCTs on the effectiveness of e-coaching as a cardiac 
rehabilitation programme. They report that complex e-coaching (including ≥4 
components of cardiac rehabilitation) was effective at short-term for PA, when 
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comparing to usual care. However for basic e-coaching (≤3 components) limited or 
no evidence of effectiveness was found.  
As stated previously, objective PA measures were rarely used in online 
interventions. Hence we expected to increase our knowledge on PA tracking, by 
studying different monitors as shown on Chapter 5. We concluded that the Fitbit 
Charge HR and MIO fuse had a high reliability and validity for number of steps in 
cardiac patients on phase III of cardiac rehabilitation. In line with our results, Alharbi 
et al (21) found valid and reliable the use of Fitbit-Flex as an alternative device for 
PA monitoring in cardiac patients. 
Most of the instruments for self-report PA measures in cardiac patients have great 
variability, poor validity and reliability and are more suited to epidemiologic studies 
rather than assessing intervention outcomes where responsiveness to intervention 
is vital (22). Hence, establishing the reliability and validity of some activity trackers 
added value to the present PhD project, since we intended to further increase the 
knowledge of their utility in CAD patients participating in telemedicine and tele-
rehabilitation programs. 
Participants in the TRiCH study had an average BMI of 27.4 kg/m2 that was 
maintained throughout the intervention in the short-term (Chapter 3) and longer-
term follow-up (Chapter 4). In line with our findings, Dale et al (23) observed no 
effect on dietary behaviours or smoking cessation of mHealth interventions in the 
CVD population. A separate meta-analysis of 36 weight loss studies found that 71% 
of the studies reported some form of weight loss, although participants and 
heterogeneity precluded a summary estimate of weight loss achieved through digital 
health interventions (24). It is possible that changing dietary behaviours may be more 
difficult via mHealth. However, more research is needed before conclusions can be 
drawn on this topic. 
On Chapter 3 we described that participants of the TRiCH study maintained their 
systolic blood pressure and diastolic blood pressure, the same result were found in 
the long-term (Chapter 4).  Purcell et al (25) reported in a review of reviews that the 
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use of tele-monitoring for patients with hypertension and heart failure was associated 
with multiple benefits. They included four reviews which investigated hypertension 
and CVD management using blood pressure as an outcome measure. All reviews 
reported significant reductions in blood pressure with various interventions 
(telephone-based intervention/internet-based intervention). We agreed with their 
conclusion that given the concomitant changes in extraneous variables such as 
medication use and lifestyle risk factors that occurred around the interventions is 
difficult to ascertain which specific aspects of tele-monitoring interventions might 
explain improvements in the blood pressure values. 
When reporting on the effects of tele-monitoring in Chapters 3 and 4, surprisingly, 
we discovered that little is known about skeletal muscle strength in cardiac patients 
suffering from other diseases than heart failure (26). Therefore, we hope our results 
could increase the interest in this research field. 
Overall, our TRiCH study assessed the effects in both the short and long-term on 
exercise capacity, cardiovascular risk factors, PA and HRQoL by means of a 
randomized controlled study, improving the body of evidence in favour of a tele-
monitoring intervention that will maintained the benefits of a traditional CB cardiac 
rehablitation program after the completion of phase II cardiac rehabilitation. 
Different components of tele-monitoring in cardiac rehablitation programs 
In simple terms telemedicine refers to the delivery of medical health services at a 
distance, there is no single or uniform telemedicine or telehealth service as such 
(27). As can be seen in Figure 14, Telemedicine includes telehealth and remote 
patient management, telecare and teledisciplines (including teleradiology, 
teledematology, telescreening,etc). 
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Figure 14. Different components of telemedicine. Adapted from COCIR (28) 
 
Cardiac tele-rehabilitation is a care delivery strategy that is developing a role in 
secondary prevention after acute myocardial infarction according to the European 
Association of Preventive Cardiology in collaboration with the Acute Cardiovascular 
Care Association and the Council on Cardiovascular Nursing and Allied Professions 
(29). They identified cardiac tele-rehabilitation as a supplement and/or alternative to 
conventional CB services since it has shown potential to address some of traditional 
CR barriers through for example HB cardiac rehabilitation programs (30). 
Tele-rehabilitation interventions however, as described by Frederix et al (31) 
employed only one or two core components of cardiac rehabilitation. According to 
the author, PA is the parameter most frequently evaluated. This tendency is 
explained by the benefits of a high cardiovascular fitness evidenced by reductions 
of 10% to 25% in mortality risk (in both men and women) per increase of 1 MET in 
exercise capacity (32, 33). Furthermore, a higher physical activity patterns and 
cardiovascular fitness have an important moderating role on the traditional 
cardiovascular risk factors (34). Studies suggest that even modest amount of 
exercise will be sufficient to achieve significant health benefits (jog slowly as little as 
5-10 minutes per day) (35). In our TRiCH study, we employed the PA component, 
but the focus on phase III of cardiac rehabilitation increased the interest in our results 
since is a CR phase that has not been greatly investigated.  
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Further analysis will be develop in the future research section of this discussion in 
relation to the wide heterogeneity with respect to patient population, tele-
rehabilitation intervention used, and primary and secondary outcome measures in 
tele-rehabilitation with CAD population.  
Safety and cost-effectiveness of HB programmes with tele-monitoring guidance 
Patients undertaking HB cardiac rehabilitation are not necessarily at greater risk of 
adverse events, but because emergency services are not immediately available, 
future research should give consideration to patient safety, especially in specific 
circumstances such as traffic hazards, unsafe walking surfaces or areas with 
inadequate public safety (36) as well as patients in medium to high CV risk. In 
Chapters 3 and 4 we established that HB cardiac rehabilitation is a feasible, safe 
and comparable strategy to the conventional in-hospital rehabilitation approach in 
patients with low to medium risk, as have been shown by previous studies (37) (18).  
Although cost-effectiveness of tele-rehabilitation has been rarely researched, 
Frederix et al, in the Telerehab III trial (13) showed that a supplemental programme 
of cardiac tele-rehabilitation lasting 6-months remained cost-efficient even 2 years 
after ending the tele-intervention. However, other publications do not support this 
findings. The BRUM study compared the costs of a home-based CR programme that 
used a heart rate manual compared to a CB cardiac rehabilitation in 525 CAD 
patients finding higher costs in the HB programme (€ 234 vs € 186) (38). 
Complementary, Teledialog study evaluated the cost-utility of cardiac tele-
rehabilitation in 151 CAD, heart failure and valve surgery patients, concluding that 
tele-rehabilitation was not a cost-effective strategy (39). 
It is not possible to establish the cost-effectiveness of the TRiCH study since it was 
never a purpose of our project; however, further research would clarify the costs of 
such interventions. 
Strengths and limitations of the present doctoral thesis 
The TRiCH study was strengthened by the design of a randomized controlled trial 
using a three arm, parallel group, being one of the few studies including a control 
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group and two intervention groups (HB and CB) which allow us to draw an accurate 
conclusion concerning treatment efficacy (40). Including patients in phase III cardiac 
rehabilitation is also a big strength of the study since most of the publication centred 
its interventions in phase II cardiac rehabilitation program. The longer-tem follow-up 
can also be considered a strength since the number of studies are disappointingly 
low; thus, the TRiCH study with a follow-up period of one year is one of the few 
studies that allowed a reasonable time frame to assess long-term effects of a tele-
monitoring program during phase III of cardiac rehabilitation.  
Another strength of our research is the objective evaluation of PA through the use of 
accelerometer. The ability to assess energy expenditure and estimate PA in free-
living individuals is extremely important in the global context of non-communicable 
diseases like CAD (41). While some studies contend that it is possible for self-report 
PA questionnaires to assess some aspects of EE, most agree that questionnaires 
are less accurate than objective methods such as SenseWear armband used in our 
research (42). Recording objectively free-living activity behaviour may be helpful in 
quantifying levels of activity and could provide insights into important symptoms in 
the future (42).  
The main limitation of our study is related to the recruitment of participants that took 
longer than anticipated, then only 90 patients were included in the study, thus our 
results must be analysed carefully, another limitation is as with most randomized 
control trials, missing outcome data mostly in muscle strength and PA due to 
technical problems or incomplete data; this information was missing completely at 
random.  
Future research  
This document highlights the diversity that tele-monitoring and tele-rehabilitation 
brings to cardiac rehabilitation of CAD patients, however it also brings the attention 
to factors that could point the way for future research. 
Currently, the main shortcomings might be related to four topics being: a) 
Heterogeneous data availability and variable quality of the publications that limits the 
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possibility to draw conclusions on the effectiveness of HB cardiac rehabilitation with 
tele-monitoring guidance. b) A wide definition of HB cardiac rehabilitation and its 
components c) Significant variance in the follow-up of the HB program interventions 
d) Wide technology available to monitor patients at distance. 
Today, the need to design, evaluate, and implement evidence-based alternative 
approaches to traditional cardiac rehabilitation that help provide all appropriate 
patients affordable access to clinically effective secondary prevention intervention is 
clear (16). The usual model of care for people with CVD includes regular visits to the 
doctor and emergency services, involving high healthcare costs. However, new 
methods to deliver healthcare using mobile digital communication devices, mobile 
health (mHealth), may increase the number of patients treated while facilitating 
patient self-management and saving costs (43). A recent report found that 77% of 
adults aged 65 years old owned a mobile phone and over half (59%) used the 
Internet (23). Since 2011, there has been a 30% increase in ownership of 
smartphones with nearly 62% owners reporting using their cell phone to seek health 
information within the past year (44). Clearly, telehealth can combine the 
accessibility of HB cardiac rehabilitation with the specialist monitoring, interaction 
and support of centre-based programmes (45).  
The meta-analysis of Huang et al. (8) that included nine randomized controlled trials 
compared a total of 781 participants in a CB cardiac rehabilitation with telehealth 
versus 765 participants in CB group; they found that exercise in telehealth 
intervention varied in total duration (six weeks to six months), frequency (1-6 
sessions/week) and session length (25-60 min/session). They suggested however 
that telehealth intervention delivered CR does not have significantly inferior 
outcomes compared to a CB supervised program in low to moderate risk patients. 
Rawstorn et al (45) described 11 studies including 1189 patients that compared 
telehealth cardiac rehabilitation against usual care or CB cardiac rehabilitation. In 
their meta-analysis, telehealth technologies were mainly fixed-line telephone, 
biosensors (accelerometry, heart rate) and websites. Among studies that described 
exercise prescription parameters, telehealth interventions comprised ≥2 to ≥5 
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sessions per week, lasting 30-60 min per session with exercise intensity increasing 
from moderate (40-60% peak capacity) to vigorous (70-85% peak capacity) through 
telehealth cardiac rehabilitation programs with walking as the predominant exercise 
mode. The main finding also support the idea that telehealth cardiac rehabilitation is 
at least as effective, and in some cases more effective than CB cardiac 
rehabilitation..  
Finally, Frederix et al (31) include in their meta-analysis 37 publications, they 
described wide heterogeneous studies regarding study population and 
implementation of tele-intervention that made the inter study comparison difficult. 
Furthermore, it was not always clear whether tele-rehabilitation intervention were 
compared with conventional cardiac rehabilitation or whether the impact of the 
addition of tele-rehabilitation intervention on top of conventional cardiac 
rehabilitation was assessed. They also concluded that tele-rehabilitation could be a 
feasible and effective additional and/or alternative form of rehabilitation, compared 
to conventional in-hospital cardiac rehabilitation. A review of reviews found the 
majority of SMS interventions delivered to healthy and clinical populations were 
effective when addressing PA, smoking cessation or medication adherence which 
remains understudied in the CVD population (23); it is unknown whether more 
complex tele-monitoring interventions are effective at changing behaviour as more 
studies are needed. On the other hand, exercise and PA has a “dose-response” 
relationship with CVD risk (46). Moreover, a higher exercise capacity (VO2P) is 
associated with an improvement in mortality risk. It is a legitimate concern that if 
patients engaging in cardiac rehabilitation do not achieve the correct dose of 
exercise, a physiological benefit is unlikely.  
Thus, future randomized controlled trials on diverse populations could include more 
components in the tele-monitoring intervention, and could reproduce the training 
parameters used in previous publications like the TRiCH study. 
Currently, a clear definition for “HB cardiac rehabilitation” is lacking. As such, the 
contents of these interventions varied widely and ranged from the use of manuals 
for a healthier lifestyle to personalized exercise prescriptions (47). HB cardiac 
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rehabilitation programmes were first reported in the early 1980s and were defined 
by Jolly et al (38) as a structured programme with clear objectives for the participants 
that also included monitoring, follow-up, visits, letters or telephone calls from staff, 
or at least self-monitoring diaries. Clark et al (48) considered the HB secondary 
prevention interventions as formalized interventions for the secondary prevention of 
CVD with predominant or exclusive HB components. These interventions can be 
provided in a range of ways including paper, face-to-face, electronic, or telephone-
based methods. In general, HB cardiac rehabilitation programmes can include 
supervised and unsupervised elements and increasingly use technology or 
“telehealth” interventions to support or encourage exercise or behaviour change or 
to overcome barriers of time and distance (49).   
Using telehealth to deliver cardiac rehabilitation has been proposed as an innovative 
way of improving patient’s uptake, choice and access (50). Telehealth is part of the 
“telemedicine” group that has a wide definition and is considered to be medicine 
practice at a distance and corresponds to a wide range of telemedicine applications 
(50). Telemedicine interactions have been of two types, either taking place in real-
time such as for video conferences, or asynchronously such as store and forward 
transmission of data from HB measurements or require the patient to do something 
(e.g. transmitting home-measurement values using conventional telephones or 
smartphones). A systematic review indicate that telehealth cardiac rehabilitation 
improves cardiovascular risk factors, health-related quality of life, adverse events 
and cost-effectiveness; however, few studies have used telehealth to deliver or 
monitor structured, individualised, prescriptive exercise training in a manner similar 
to CB cardiac rehabilitation (44). Furthermore, most studies explorePA tele-
monitoring rather than tele-rehabilitation, since it includes other important core 
components (nutritional counselling, risk factor management, psychosocial 
management) (51). A review from Frederix et al (31) found that only 10% of their 
assessed tele-rehabilitation trials included multi core component approach; therefore 
the possible value of this innovative way of remote rehabilitation could be 
underestimated.  
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Thus, future trials including all components of traditional CB cardiac rehabilitation 
will be necessary to confirm the effectiveness of HB tele-rehabilitation for enhancing 
PA and exercise adherence, changes to a healthier lifestyle and medication use. 
To be successful, follow-up strategies need to embrace overall risk reduction, and 
at the same time, interventions must be accessible and relevant to clinical practice 
(52). Duff et al (53) identified a follow-up duration of HB cardiac rehabilitation 
interventions ranging from 3 weeks to 16 months, which meant that was impossible 
to pool results in a meta-analysis. Supervía et al (43) described that the maximum 
follow-up reported in their review was six months, with a high participant drop-out 
rate in most of the studies. This is a troubling finding considering that secondary 
prevention is a lifelong intervention, underscoring the need for studies with longer 
follow-up (43).  
Given the secondary prevention goal of cardiac rehabilitation, a follow-up period of 
1 year is negligible, and there is an urgent need for studies evaluating the effect of 
cardiac rehabilitation over even longer periods of time (47). It has already been 
shown that a reinforced, multifactorial educational and behavioural intervention with 
multiple one-to-one support sessions (between the patient and a medical supervisor) 
is effective in decreasing the patient´s cardiovascular risk profile up to three years 
after phase II cardiac rehabilitation; however, when it comes to HB with tele-
monitoring guidance Claes et al described a disappointingly low number of studies 
available evaluating the longer-term effects of cardiac rehabilitation (47).  
Since assessing the long-term effectiveness of mHealth interventions will prove the 
value of mHealth in clinical practice we stress the importance of further research in 
the longer-term focusing on exercise adherence. We considered that a one-year 
follow-up may be insufficient to detect real lifestyle changes. 
Tele-monitoring is defined as the use of information technology to monitor patients 
at a distance, including “the use of audio, video, and other telecommunications and 
electronic information processing technologies to monitor patient status at a 
distance” (54). HB cardiac rehabilitaiton should ideally permit functional monitoring 
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and in order for telemedicine to have a significant impact on healthcare systems, 
mHealth should offer a sustainable, low-resource and cost-effective approach to a 
wide range of people, improving patient outcomes, such as reducing hospitalization 
rates and increasing medication adherence (43). The uptake of mHealth for CVD 
has been slow, but despite lower mobile phone usage among older adults, recent 
reviews have shown that CVD population are able to use and engage with 
technology (23). Furthermore, mobile phones are now omnipresent, with world-wide 
usage rates nearing 100% and recent estimates suggest 7.7 billion mobile 
broadband subscription in 2020, while the number of smartphone subscriptions is 
expected to equal about 70% of the world´s population (55).  
The most researched form of mHealth has been the use of text or short-message 
service (SMS), found to facilitate significant positive effects on health outcomes 
and/or behaviours (23). Previous reviews have reported that the effective mHealth 
behaviour change interventions were those that were theory-based and offered 
personalized, tailored and bi-directional messaging (56). However Pfaeffli et al (23) 
found that the degree of personalization or tailoring did not appear to influence 
outcomes. Furthermore, establishing reliable and clinically meaningful digital health 
data is still problematic, while some apps and devices are developed using evidence-
based guidelines and are continuously evaluated, most remain unevaluated (55); 
this can lead to consumer confusion, reluctant promotion by healthcare providers 
and unnecessary consumption of health care resources.  
The main factors associated with low attendance to cardiac rehabilitation programs 
have been review previously, and include older age, lower income and a lower 
understanding of the severity or their illness (57). Smoker patients, unmarried, 
unemployment, and a lower socioeconomically status and living distant from the 
programme venue are also commonly named (58); thus, the use of home-based 
cardiac rehabilitation with tele-monitoring guidance carries the potential to increase 
participation of these specific groups in cardiac tele-rehabilitation programmes. 
Thus, future studies should target populations known to have a lower participation 
on cardiac rehabilitation programs who might potentially benefit the most through the 
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use of mobile applications as well as the validity and reliability of the devices used 
for their mHealth interventions.  
 
General conclusion 
From the present PhD thesis we can conclude in the short term: 
- Home-based cardiac rehabilitation with tele-monitoring guidance can be an 
effective alternative to centre-based cardiac rehabilitation for further improving 
exercise capacity following phase II cardiac rehabilitation in coronary heart disease 
patients. 
- - Home-based cardiac rehabilitation is safe in clinically stable coronary 
artery disease patients. 
- To increase the body of evidence, targeted populations, individualized training 
programs and multicentre studies are needed. 
In the long-term we can conclude: 
- Three-month home-based exercise cardiac rehabilitation with tele-monitoring 
is insufficient to improve the exercise capacity of coronary artery disease patients in 
maintenance phase. 
- - Given the significant heterogeneity and scarcity of longer-term follow-
up studies for tele-monitoring intervention in phase III of cardiac rehabilitation, further 
studies reproducing previous protocols in different coronary artery disease 
population might be needed to increase the evidence of its effectiveness. 
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INTRODUCTION 
Patients with coronary arterial disease commonly present endothelial dysfunction, 
characterized by a compromised capacity of vessels to dilate due to elevated levels 
of reactive oxygen species. Resveratrol (RV) is a polyphenol with anti-oxidant, anti-
inflammatory and cardio-protective properties (1). In humans, RV has been shown 
to improve flow mediated dilation (FMD) in obese type 2 diabetic men (2); but blunts 
the positive effects of regular exercise in healthy young men (3). Considering that 
the effects of RV may occur in conditions with elevated systemic inflammation and 
oxidative stress, we reasoned that acute supplementation with high RV doses would 
improve FMD in older CAD patients after rehab following coronary intervention.  
METHODS 
CAD patients (45-75 yr) from a cardiac rehabilitation program participated in a 
placebo-controlled single-blind crossover study (according to guidelines of the 
Declaration of Helsinki; ethical approval ML9734). Patients with a history of CAD had 
either a percutaneous coronary intervention (PCI), or post-coronary artery bypass 
graft (CABG). Patients attended the laboratory on two occasions: once after RV 
supplementation and once after supplementation with placebo. During each visit, 
patients underwent measurements of endothelial function in the brachial artery.  All 
tests were performed in a fasted state, one hour after ingestion of the last capsule 
(RV or placebo,) and a seven-day wash-out period in-between.  
Both RV (98.57% pure, polygonum cuspidatum extract; microcrystalline cellulose, 
21st Century Alternatives, GB) and placebo were given as 330 mg capsules, 
consumed every 8 hours (i.e. three times per day) for three days. The last capsule 
was ingested one hour before the experimental session on the fourth day. Brachial 
artery images were obtained with a 12-MHz linear-array vascular ultrasound 
scanning transducer (Vivid 7; GE Healthcare) and longitudinal images recorded 
(Flomedi, Brussels, Belgium) 30 seconds before occlusion and for 150 seconds 
following cuff deflation.  
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Statistical analyses were performed using SPSS (Chicago, USA). The Shapiro-Wilk 
test was used to check normality of the data. A repeated-measures ANOVA with as 
within factor RV (placebo vs. RV) and between factors condition (PCI vs. CABG) 
was used to assess effects of RV treatment, and PCI and CABG, respectively. 
Statistical significance was established at P<0.05 (2-tailed).  
RESULTS 
There was a significant intervention * RV interaction (p = .004) reflected by an RV-
induced reduction in FMD in patients who underwent PCI, and an RV-induced 
increase in FMD in patients who had a CABG (Figure 15). 
Figure 15. Individual and average resveratrol-induced changes in FMD 
 
A: Individual and B: average resveratrol-induced changes in flow-mediated dilation (FMD) in patients 
that had a percutaneous intervention (PCI: ---○) or post-coronary artery bypass graft (CABG: 
_____●).*: Significantly different from corresponding baseline; #: significantly different from other 
group. Data are mean ± SEM. Interaction resveratrol x intervention P = .004. 
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DISCUSSION 
The key finding of our study is that RV has differential effects on vascular function in 
older CAD patients, depending on the type of clinical intervention they have 
undergone. In the subset of patients who had undergone PCI, while their FMD values 
were within the normal expected range (2), acute RV supplementation, led to a 
significant reduction in FMD. On the contrary, for the CABG patients, 
supplementation led to a significant improvement in FMD. 
Prior to RV supplementation, compromised endothelial function was evident in the 
patients with CABG, as reported previously (4). This is not surprising, given the fact 
that CABG patients usually present with more severe CAD, affecting multiple vessels 
and having co-morbidities (5). Treatment with RV reduced FMD in the subset of 
patients with PCI but significantly improved it in CABG. In a rabbit model of CABG, 
RV administration over 8 weeks protected against EC injury (6). In addition, in 
isolated normal murine femoral arteries, RV improved acetylcholine-induced dilation 
while inhibiting flow-mediated dilation, suggesting that RV might improve dilation via 
endothelial independent mechanisms, by acting directly on the smooth muscle cell 
layer (7). Whilst the mechanisms leading to improved dilation after CABG but not 
PCI intervention are unclear, our study suggests that RV might have differential 
effects on endothelial function depending on shear stress and/or inflammatory status 
(1)1. Our findings have important implication for patient stratification towards 
therapeutic intervention.  
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APPOSITIONS 
In individuals with a well-balanced diet, nutritional supplementation might not confer 
additional health benefits.  
Excessive reliance upon telemedicine and digitalizing health could be detrimental of 
traditional health care personnel-patient relationships and against the risk and 
responsibilities of each part. 
Physically active health care providers are more likely to provide physical activity 
advice to their patients. 
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LIST OF ABBREVIATIONS 
AEE Active energy expenditure 
BMI Body mass index 
CABG Coronary artery bypass grafting 
CAD Coronary artery disease 
CB Centre-based 
CG Control group 
CHD Coronary heart disease 
CR Cardiac rehabilitation 
CVD Cardiovascular disease 
FMD Flow mediated dilation 
HB Home-based 
HDL - C High-density lipoprotein cholesterol 
HG Hand grip 
HOMA Homeostasis assessment model 
HR Heart rate 
HRR Heart rate reserve 
HRQoL Health related quality of life 
ICC Intraclass correlation coefficient 
LDL - C Low-density lipoprotein cholesterol 
MAD Mean absolute difference 
MAPE Mean absolute percentage error 
METs Metabolic equivalent (of task) 
MRT Mean response time 
NO Nitric oxide 
PA Physical activity 
PCI Percutaneous coronary intervention 
RER Respiratory exchange ratio 
RV Resveratrol 
SRT Sitting-rising test 
TRiCH Telerehabilitation in coronary heart disease 
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VAT Ventilatory anaerobic threshold 
VO2P Peak oxygen uptake 
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